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1 Abstract  
Rap1GAP is the founding member of a family of GTPase activating proteins (GAPs) 
for the small guanine nucleotide binding protein (GNBP) Rap1, which show no 
sequence homology to GAPs of other small GNBPs. Rap1 does not have a catalytic 
glutamine residue which is essential for the intrinsic and GAP mediated GTP 
hydrolysis of all other small GNBPs. In this thesis, the structure and the mechanism 
of GAP catalysed GTP hydrolysis are examined.  
Most GAPs provide a catalytic arginine residue to the GNBP to complement the 
incomplete catalytic machinery. However, site-directed mutagenesis revealed that 
Rap1GAP does not employ a catalytic arginine. To understand the novel reaction 
mechanism, the structure of Rap1GAP was determined by X-ray crystallography to a 
maximal resolution of 2,9 Å. Initial phases were obtained by selenomethionine 
substituted crystals and a SIRAS phasing protocol. The structure was built and 
refined to an Rcryst= 23,4% and an Rfree of 27,6%. 
Two Rap1GAP dimers were observed in the asymmetric unit, consistent with gel 
filtration experiments in which also dimerisation was observed. A Rap1GAP 
monomer consists of two domains. Both domains show a mixed α-β fold and were 
named dimerisation and catalytic domain, respectively. Surprisingly, the catalytic 
domain has structural similarity to the G domain of GNBPs itself suggesting a 
common evolutionary origin. No structural similarity to any other GAP was observed. 
By site-directed mutagenesis, it was shown that dimerisation is not required for GAP 
function. However, both domains are necessary for full catalytic activity. Mutations 
around a highly invariant helix, the putative interaction helix, dramatically reduced 
GAP activity. Using a single-turnover fluorescence reporter assay it could be 
conclusively proven that Rap1GAP employs a catalytic asparagine from the 
interaction helix to stimulate GTP hydrolysis in Rap1. In the absence of this 
asparagine side-chain Rap1GAP was completely inactive but could still bind to 
Rap1•GTP. In contrast to the wild-type, the Rap1GAPN290A mutant can not associate 
with a transition state mimic of Rap1 GTP hydrolysis. Thus, Rap1GAP is the first 
example of a GAP which provides a catalytic asparagine for catalysis. Based on the 
analysis of various mutants, a model for the interaction of Rap1GAP with Rap1 is 
proposed.   
The results of this thesis have implications for the disease Tuberous sclerosis. Loss 
of function mutations in the Rap1GAP homologue Tuberin are associated with this 
disease and can be rationalised in the view of this work.  
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2 Introduction 
2.1 Guanine nucleotide binding proteins 
2.1.1 The molecular switch 
Guanine nucleotide binding proteins (GNBPs) are involved in a wide range of cellular 
processes including protein synthesis, sensual perception, vesicular transport and 
signal transduction cascades leading to cell proliferation and cell differentiation. Most 
GNBPs regulate these processes rather than provide energy for mechano-chemical 
work or chemical synthesis. Typically, GNBPs exist in an active GTP bound 
conformation and in an inactive GDP bound state (Bourne et al., 1990), therefore 
acting as a molecular switch (Figure 1). The GTP bound state has high affinity for 
interacting proteins which are referred to as effector molecules whereas the GDP 
bound state has low affinity and poorly interacts. In turn, the effectors are relocalised 
to their specific subcellular sites by this interaction or their activity is modulated. 
To reach the active state, GDP has to be released and a new GTP molecule has to 
be bound. Since this reaction is intrinsically too slow to regulate cellular processes it 
can be accelerated by the action of guanine nucleotide exchange factors (GEFs). 
GEFs catalyse nucleotide dissociation and allow GTP which is more abundant in the 
cell to bind. Also the intrinsic GTPase reaction of GNBP is slow. For efficient 
inactivation, the intrinsic reaction can be drastically stimulated by the action of 
GTPase activating proteins (GAPs). 
GNBP
GTPGDP
GNBP
GTP GDP
H O2Pi
Effector
proteins
onoff
GAP
GEF
 
Figure 1. The molecular switch of guanine nucleotide binding proteins. For explanation see 
text.  
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2.1.2  Overview of the GTPase superclass 
Nucleotide binding proteins appear in a number of different folds (Vetter and 
Wittinghofer, 1999) including the di-nucleotide binding (Rossmann) fold, the protein 
and histidine kinase fold and the mono-nucleotide binding fold (P-loop containing 
nucleotide triphosphate (NTP) hydrolases). P-loop containing NTP hydrolases share 
the most abundant protein fold in most organisms and comprise 10 to 18% of all 
gene products (Koonin et al., 2000). This family can be divided in at least seven 
further lineages one of which is the GTPase superclass (Leipe et al., 2002). 
The GTPase superclass was recently classified anew based on sequence and 
structure alignments of all available bacterial and eukaryotic GNBPs (Leipe et al., 
2002). Two major branches could be identified which were named the TRAFAC 
(translation factor-related) and the SIMBI class (signal recognition particle, MinD and 
BioD). The best known members of the SIMBI class are the signal recognition 
particle GTPase (Ffh in bacteria) and the α-subunit of the signal recognition particle 
receptor (FtsY in bacteria) (Freymann et al., 1997). They exist in bacteria and 
eukaryotes and are involved in co-translational cellular targeting of nascent secretory 
and membrane proteins. The TRAFAC class contains most notably the translation 
factor superfamily, the Myosin-kinesin and the Ras-like superfamily.  
Initiation factors IF2 (eIF5B in eukaryotes), eIF2γ (in some bacteria SelB) and 
elongation factors EF-Tu and EF-G are the four members of the translation factor 
superfamily that appear ubiquitously in bacteria and eukaryotes (Leipe et al., 2002). 
eIF2γ forms a ternary complex with GTP and Met-tRNAiMet and mediates with other 
initiation factors the binding of tRNAiMet to the ribosome (reviewed in Sonenberg and 
Dever, 2003). GTP hydrolysis in eIF2γ is triggered in a reaction which requires 
among others initiation factor IF2/eIF5B. EF-Tu is a three-domain protein that forms a 
ternary complex with aminoacyl-tRNA and controls incorporation of the correct amino 
acids into the peptide chain (reviewed in Ogle et al., 2003). The five-domain protein 
EF-G catalyses translocation of tRNAs on the ribosome. The origin of other factors 
involved in protein biosynthesis, e.g. the release factors, differs in the three kingdoms 
of life (Leipe et al., 2002). 
The eukaryotic cellular motor ATPases kinesin and myosin were grouped in the 
myosin-kinesin superfamily of TRAFAC GTPases. It has been argued that these 
proteins have evolved from an ancestral GTPase at the onset of eukaryotic evolution 
and have lost later their specificity towards GTP (Leipe et al., 2002). Members of the 
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dynamin family which are involved in the budding of clathrin-coated vesicles (Urrutia 
et al., 1997), and the GB1 family including GBPs (Prakash et al., 2000), are also 
grouped in this superfamily.  
Heterotrimeric G-proteins appear exclusively in eukaryotes and more than 20 
members are known (Sprang, 1997). They are activated by cell-surface receptors of 
the seven-transmembrane-helix class and regulate intracellular effectors such as 
adenylyl-cyclase or phospholipase Cβ.  
Members of the Ras superfamily exist predominantly in eukaryotes. The exact 
classification of this superfamily varies (Bourne et al., 1990; Garcia-Ranea and 
Valencia, 1998; Leipe et al., 2002). The group of 20-25 kD GNBPs with Ras as most 
prominent member was called the small GNBPs. They were first grouped as a 
separate superfamily composed of the Ras, Rab, Rho, Ran and Arf/Sar1 family 
(Garcia-Ranea and Valencia, 1998), albeit it was recently suggested that the family of 
hetero-trimeric GNBPs should also be included in this superfamily (Leipe et al., 
2002). More than 100 small GNBPs have been identified in eukaryotes (reviewed in 
Takai et al., 2001). Ras family members mainly regulate gene expression, whereas 
GNBPs of the Rho/Rac family control gene expression and cytoskeletal 
reorganisation. Members of the Ran family regulate nucleo-cytoplasmic transport 
during G1, S, G2 and among others microtubule organisation during M phase. Rab 
and Arf GNBPs control intracellular vesicle trafficking. A dendrogram showing the 
evolutionary relation between the small GNBPs is depicted in Figure 2. 
 
Figure 2. Dendrogram of the family of small GNBPs (from Takai et al., 2001) 
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2.1.3 Biochemical and structural features of small GNBPs  
Ras consists of 189 amino acids and is the best characterised small GNBP 
(Wittinghofer and Waldmann, 2000). It is considered a paradigm for the complete 
family and its biochemical features are often representative for the other small 
GNBPs as well. 
Ras is located in the plasma membrane by means of a farnesyl and a palmitoyl 
anchor which is required for its function in vivo. As most other small GNBPs, it has an 
extremely high affinity for both GDP and GTP with a KD in the picomolar range 
(Wittinghofer and Waldmann, 2000). No other standard nucleotide binds to Ras with 
a comparable affinity showing the high specificity for guanine nucleotides. The 
β-phosphate is required for high affinity binding since guanosin monophosphate 
(GMP) has a 106-fold reduced affinity in comparison to GDP/GTP. The binding affinity 
strongly depends on the presence of magnesium ions. When magnesium ions are 
absent, the dissociation rate constant (koff) increases by many hundredfold with a 
concomitant increase in the equilibrium dissociation constant (KD) (John et al., 1988). 
Available crystal structures demonstrate that Ras shares a common structural core - 
the G domain fold - with the complete class of TRAFAC GTPases (Leipe et al., 2002; 
Sprang, 1997). The G domain fold comprises approximately 200 residues and 
consists of a six stranded mixed β-sheet surrounded by five α-helices (Figure 3). The 
most highly conserved elements in this domain are the five polypeptide loops that 
form the guanine nucleotide-binding site called G1 through G5 (Figure 3, Bourne et 
al., 1991). 
 
Figure 3. Structure of the Ras protein in the GppCp•Mg bound form with the conserved 
elements and G-box regions labelled (from Sprang, 1997).  
Introduction 
6 
The G1 motif, better known as P-loop, connects strand β1 to helix α1. It contains the 
consensus motif GxxxxGK(S/T) (in Ras amino acids 10-17) and forms a ring-like 
structure which wraps tightly around the β-phosphate of GTP and GDP. The 
C-terminal serine of this motif (serine 17 in Ras) is complexed to the magnesium ion 
which is essential for high affinity binding of the nucleotide.  
The connection between helix α1 and strand β2 contains a conserved threonine 
residue of the G2 motif involved in Mg2+ coordination and in direct binding to the 
γ-phosphate (threonine T35 in Ras). Also the G3 motif (DxxGQ/H/T) is involved in 
phosphate binding. The conserved aspartate (aspartate D57 in Ras) binds the 
magnesium ion via a water molecule and glycine G60 binds via a main chain contact 
directly to the γ-phosphate. Motif G4 (consensus NKxD with asparagine N116 in Ras) 
is located between strand β5 and helix α4 and is partly responsible for the 
recognition of the guanosin base. The (T/G)(S/C)A(K/T/L) (G5) motif (serine S145 in 
Ras) is located between strand β6 and helix α5. It does not participate directly in the 
guanine base recognition besides a main chain interaction of alanine A146. However, 
it stabilises residues of the G4 motif and hydrophobic residues involved in binding of 
the guanine base (e.g. phenylalanine F28 in Ras). The network of conserved 
interactions between Ras and the GTP analogue GppNHp is shown in Figure 4. 
 
Figure 4. Interactions of the Ras and the GTP analogue GppNHp with selected, conserved 
residues (from Wittinghofer and Waldmann, 2000) 
 
Introduction 
7 
Two elements in GNBPs have been shown to undergo major conformational changes 
upon GTP hydrolysis, the switch I and switch II region (reviewed in Vetter and 
Wittinghofer, 2001). Conformational changes in switch I (amino acids 32-40 in Ras) 
are mediated mainly by the conserved threonine T35 of motif G2, conformational 
changes in switch II (amino acids 61-67 in Ras) by the conserved glycine G60 of 
motif G3. Due to the interaction of these residues with the γ-phosphate, the switches 
become stabilised in the GTP bound form. In contrast, the switches are rather mobile 
in the GDP bound form (Figure 5).  
 
Figure 5. Superposition of selected Ras-related proteins in the GDP and the GTP bound form. 
Whereas in the GTP bound form, all switches are stabilised in a similar 
conformation, they are much more flexible in the GDP bound form and show 
divergent conformations. Extra elements in the structures of Rho, Arf and Ran are 
highlighted (from Vetter and Wittinghofer, 2001). 
The switches are the main determinants for binding of effector molecules. In the case 
of Ras, switch I was shown to bind to an 80 residues Ras Binding Domain (RBD) of 
effectors (Nassar et al., 1995; Huang et al., 1998; Vetter et al., 1999; Pacold et al., 
2000). Although there is no sequence homology among the RBDs of different 
effectors, all examined RBDs show a ubiquitin-like fold. The RBD and Ras•GTP 
interact via an interprotein β-sheet. Besides some main chain interactions, most 
contacts are mediated by hydrophilic side chains. RBDs from different proteins, 
however, use different residues for interaction (Joneson et al., 1996). 
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2.1.4 The hydrolysis reaction  
The intrinsic GTPase reaction of small GNBPs is slow, for Ras in the range of 
0,02 min-1, and is strictly dependent on the presence of divalent cations (Wittinghofer 
and Waldmann, 2000). A water molecule close to the γ-phosphate and in hydrogen 
bond distance to glutamine Q61 is considered to be the attacking nucleophile, and 
mutations of this glutamine to most other amino acids dramatically reduce the 
intrinsic GTP hydrolysis (Der et al., 1986; Krengel et al., 1990; Prive et al., 1992). 
Based on NMR studies with various Ras mutants and by determining intrinsic GTP 
hydrolysis reaction rates at various pH, a substrate assisted catalysis was proposed 
in which the γ-phosphate itself activates the attacking water molecule by abstracting 
a hydrogen atom (Schweins et al., 1995; Schweins et al., 1997). Both the less 
charged γ-phosphate and the more reactive nucleophile (the hydroxide ion) were 
suggested to promote catalysis. The role of glutamine Q61 is thought to be the 
positioning of the attacking water molecule in vicinity of the γ-phosphate. 
A continuum of possible transition states of the GTP hydrolysis reaction ranging from 
purely dissociative to purely associative can be described (Figure 6) (Maegley et al., 
1996). The dissociative transition state is dominated by bond cleavage, so that the 
bond to the leaving group is fully broken and the bond to the incoming nucleophile is 
barely formed. To maintain charge, this leads to a loss of negative charge on the 
terminal phosphoryl group during the transition (Figure 6) and to an increase in 
charge at the β-phosphate, especially at the β-γ bridging oxygen. On the other hand 
in the associative transition state, there is a large amount of bond formation to the 
incoming nucleophile but only a small amount of bond cleavage to the leaving group. 
To maintain charge, this will result in an increase in negative charge on the terminal 
phosphoryl group (Admiraal and Herschlag, 1995). 
 
Figure 6. Associative versus dissociative mechanism (from Maegley et al., 1996). For 
explanation see text.  
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In solution, GTP hydrolysis seems to proceed via a dissociative transition state 
(Admiraal and Herschlag, 1995). It is however controversially discussed whether in 
the protein environment the transition state has a dissociative or associative 
character (Maegley et al., 1996; Cepus et al., 1998; Allin and Gerwert, 2001; 
Schweins et al., 1995; Scheffzek et al., 1997; Glennon et al., 2000; Seewald et al., 
2002).  
  
2.1.5 The Ras signal transduction pathway 
The Ras gene was originally identified as the active principle of sarcoma viruses and 
was called an oncogene (reviewed in Takai et al., 2001). Later, it was realised that 
cellular counterparts exist in mammals.   
In humans, three isoforms of Ras exist, H-Ras, N-Ras and K-Ras with a molecular 
weight of 21 kD which differ mainly at the C-terminus. From studies in Drosophila and 
C. elegans Ras was recognised as a central component in signal transduction 
pathways linking activation of cell surface receptors to gene expression in the 
nucleus (reviewed in Pawson and Saxton, 1999; Wittinghofer and Waldmann, 2000). 
Growth factors such as EGF or PDGF bind to the extracellular domain of specific 
receptor tyrosine kinases. This leads to receptor dimerisation and subsequent trans-
phosphorylation of tyrosine residues in the cytoplasmic part of the receptor. 
Phosphorylated tyrosines in a sequence specific context are recognised by proteins 
possessing specialised phospho-tyrosine binding domains, e.g. SH2 (src homology 
2) domains. In this way, the adapter protein Grb2 binds via its SH2 domain to 
phosphorylated growth factor receptor. SOS, an exchange factor for Ras and 
associated with Grb2, is thereby recruited to the membrane where it promotes GDP-
GTP exchange on Ras. Ras in the GTP bound form activates several effectors of 
which the best characterised is the protein kinase Raf. Raf phosphorylates the 
protein kinase MEK which activates the protein kinase ERK. Finally, ERK 
phosphorylates a class of transcription factors, the ternary complex factors, which 
associate with a second class of transcription factors, the serum response factors. 
The resulting protein complex initiates transcription by binding to a conserved 
promoter element, the serum response element which is present in a variety of 
genes, e.g. many transcription factors. The Ras signal is terminated by the action of 
GAPs targeted to the intracellular part of the receptor and by dissociation of the 
SOS-Grb complex upon phosphorylation by ERK.  
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Ras acts also in different pathways. It is activated by G-protein coupled receptors and 
cytoplasmic tyrosine kinases (Weiss and Littman, 1994), and it also triggers different 
pathways, e.g. by activating PI-3-Kinase or the nucleotide exchange factor for the 
small GNBP Ral, RalGEF. 
Point mutations of Ras at either position 12, 13 or 61 render the protein unable to 
hydrolyse GTP, even in the presence of GAP (Trahey and McCormick, 1987; 
Downward, 1998) thus leading to constitutively active Ras. These mutations were 
found in human tumours (e.g. Almoguera et al., 1988) indicating that a constitutive 
active Ras pathway leads to malignant transformation. It is now estimated that 30% 
of all human tumours carry activated forms of the Ras gene. Thus, the Ras pathway 
is an important target for cancer therapy (Wittinghofer and Waldmann, 2000). 
 
2.1.6 The Rap GNBPs 
Rap1 was identified by low stringency hybridisation of various cDNA libraries with 
Ras cDNA (Pizon et al., 1988) and, at the same time as K-rev1 in a screen for cDNAs 
which revert the phenotype of K-Ras transformed fibroblast (Kitayama et al., 1989). 
With more than 50% sequence identity, Rap1 is the closest relative of Ras, especially 
Switch I is highly conserved. Unlike Ras, it is modified by a geranyl-geranyl anchor 
rather than a farnesyl anchor. 
Rap1 homologues are found in all vertebrates, in Drosophila and in yeast (reviewed 
in Bos et al., 2001). The yeast homologue Bud1 is involved in selecting the new 
budding site by recruiting and activating effectors to the selected region in the cell 
(Park et al., 2002). In Drosophila, maternal and zygotic Rap1 expression is essential 
for development of the embryo, imaginal disc development and oogenesis (Asha et 
al., 1999). Drosophila Rap1 was shown to be enriched at adherens junctions, 
particularly between newly divided sister cells, and to regulate the position of these 
junctions thereby regulating cell adhesion (Knox and Brown, 2002). 
Four isoforms of Rap exist in humans, namely Rap1a, Rap1b, Rap2a and Rap2b. 
Most work has been done on Rap1a and Rap1b, which share more than 90% 
sequence identity, and in most experimental approaches, no discrimination between 
Rap1a and Rap1b (from here Rap1) has been made (Bos et al., 2001).  
Rap1 in human was shown to be ubiquitously expressed. In fibroblast, it is located in 
the mid-Golgi compartment and early and late endosomes (Beranger et al., 1991; 
Pizon et al., 1994). However, in platelets and neutrophiles, it translocates from 
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granules to the plasma membrane upon GTP loading caused by a variety of different 
stimuli (Franke et al., 1997). In malignant oral keratinocytes, it was recently 
demonstrated to translocate from a perinuclear distribution to the nucleus upon GTP 
loading. Rap1 is thus, besides Ran, the only other small GNBP which is present in 
the nucleus (Mitra et al., 2003). By fluorescent resonance energy transfer studies it 
was established that activation of Rap1 in COS cells takes place at internal 
perinuclear membranes rather than at the plasma membrane (Mochizuki et al., 
2001). 
Based on the striking similarity of the Ras and Rap1 switch I region, Rap1 interaction 
with Ras effectors was analysed (e.g. Nassar et al., 1996). All Ras effectors 
examined are able to interact with the GTP bound form of Rap1 as well. However, 
this interaction does not activate all the effectors, as shown for the Raf-Kinase 
isoform, Raf-1 (Shirouzu et al., 1998). In line with the suppression of K-Ras action in 
fibroblasts and the recent finding that Rap1•GTP can inhibit cell proliferation in 
keratinocytes (Mitra et al., 2003), this suggested initially that Rap1 has an 
antagonistic role in Ras signalling by sequestering mutual effectors in an inactive 
state. 
However, many lines of evidence suggest now that Rap1 is also able to activate 
signal transduction pathways independently of Ras. When micro-injected into 
Swiss3T3 fibroblasts, Rap1 is able to induce DNA synthesis and morphological 
changes (Altschuler and Ribeiro-Neto, 1998). In fibroblasts, Rap1 activation fails to 
interfere with Ras-dependent ERK activation (Zwartkruis et al., 1998). In PC12 cells, 
the Raf-isoform B-Raf is activated by Rap1•GTP and activates ERK, independently of 
Ras action (Vossler et al., 1997; Kao et al., 2001). B-Raf and likewise Ral-GEF 
activity are also stimulated in vitro by Rap1•GTP (Ohtsuka et al., 1996).  
The best characterised role of Rap1, however, is the activation of integrin mediated 
cell-adhesion referred to as inside-out signalling (Katagiri et al., 2000; Reedquist et 
al., 2000; Sebzda et al., 2002; de Bruyn et al., 2002). A new Rap1 effector molecule, 
RAPL, was identified which mediates this effect by linking Rap1 to the integrin LFA-1 
(Katagiri et al., 2002). This relocalisation is accompanied by an increase in integrin-
mediated cell adhesion.   
Furthermore, Rap1 was shown to be involved in the process of learning and memory 
(Morozov et al., 2003), in the development of leukaemia (Ishida et al., 2003), in 
angiogenesis and cerebrovascular diseases (Sahoo et al., 1999).  
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Activation of Rap1 can be observed upon a wide variety of stimuli, e.g. activation of 
tyrosine kinases, hetero-trimeric G-protein-coupled receptors and cell-adhesion 
molecules (McLeod et al., 1998; Posern et al., 1998; M'Rabet et al., 1998; York et al., 
1998; Zwartkruis et al., 1998). Common second messengers such as cyclic AMP, 
Ca2+ and diacylglycerol (DAG) are involved in transducing extracellular signals to 
Rap1 (Bos et al., 2001). This activation is mediated by a variety of Rap1 specific 
GEFs. C3G was the first RapGEF to be identified (Gotoh et al., 1995). Analogous to 
the Ras exchange factor SOS, it is recruited to the membrane by an SH2 containing 
adapter protein Crk and allows consequently GDP-GTP exchange of membrane 
bound Rap1 (Okada et al., 1998). Another class of GEFs are the recently identified 
Epacs which are directly activated by cyclic AMP (de Rooij et al., 1998; Kawasaki et 
al., 1998a). CalDAG-GEFs can be activated by Ca2+ influx or by diacylglycerol 
(Kawasaki et al., 1998b) . A fourth group of RapGEFs are the PDZ-GEFs which may 
be responsible for signal amplification (de Rooij et al., 1999). It was suggested that 
PDZ-GEFs are recruited by Rap1•GTP via their RBDs to the membrane and catalyse 
further GDP-GTP exchange in Rap1 (Gao et al., 2001b). The Rap1 signal is 
terminated by GTP hydrolysis in Rap1 which can be stimulated by the action of 
GTPase activating proteins (see below).  
 
2.2 GTPase Activating Proteins 
The intrinsic GTPase reaction of most GNBPs is too slow to regulate signal 
transduction processes in a meaningful time frame (reviewed in Vetter and 
Wittinghofer, 2001). Thus, GTP hydrolysis can be accelerated by GTPase Activating 
Proteins (GAPs) which typically down-regulate GNBPs in the range of a few seconds 
(Scheffzek et al., 1998). The slow intrinsic GTPase activity of EF-Tu is for example 
dramatically stimulated by the mRNA charged 70S ribosome (reviewed in Ogle et al., 
2003). GTP hydrolysis in Gα proteins can be stimulated by a family of proteins called 
regulators of G protein signalling (RGS) (Tesmer et al., 1997). Furthermore, GAPs 
specific for the Ras, Rho, Rab, Ran and Arf family members were discovered. GAPs 
for one family of small GNBPs show generally, albeit not always, sequence homology 
to each other. However, GAPs of different families share no sequence homology. 
Many GAPs have a modular architecture to fulfil various other functions in the cell.  
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2.2.1 RasGAP and the arginine finger 
RasGAP was discovered when it was found that Ras•GTP microinjected in cells was 
rapidly converted into Ras•GDP (Trahey and McCormick, 1987). The protein 
responsible for this activity was identified and is now known as p120GAP. A fragment 
comprising 334 amino acids (GAP-334) was shown to be sufficient for catalysis. The 
structure of GAP-334 showed a helical, elongated protein with a central domain of 
218 amino acids that is conserved among all RasGAPs (Scheffzek et al., 1996). 
Later, the structure of a complex of RasGAP and Ras•GDP was solved (Scheffzek et 
al., 1997) in the presence of aluminium fluoride which along with GDP/ADP is a 
mimic of the transition state of many phosphoryl transferring enzymes (Figure 7, 
Chabre, 1990). 
GAP-334 interacts predominantly with the switch regions and the P-loop of Ras. An 
exposed loop of RasGAP containing the highly conserved arginine R789 
complements the catalytic site of Ras, and the guanidium group of arginine R789 
interacts with the β-phosphate and with AlF3 (Figure 8). Additionally, the main-chain 
carbonyl oxygen of arginine R789 makes a hydrogen bond to the side-chain amide 
group of the catalytic glutamine Q61 in Ras thereby stabilising its position. Since 
arginine R789 is located in a flexible loop and points into the active site, it has been 
called the ‘arginine finger’ (Scheffzek et al., 1998).  
 
Figure 7. Structure of RasGAP in complex with Ras•GDP•AlF3 (PDB accession code 1WQ1). 
RasGAP is shown in red, Ras in orange and blue.  
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The principles of GTPase stimulation of GAP are thought to be the stabilisation of 
glutamine Q61 leading to correct positioning of the attacking water molecule and the 
provision of positive charge by the arginine residue involved in stabilising the 
transition state. 
This structure also helped to explain why mutations in glycine G12 of Ras interfere 
with the activation by GAPs. Glycine G12 is within van-der-Waals distance of the 
catalytic glutamine of Ras and the catalytic arginine of RasGAP and any mutation 
interferes sterically with the arrangement of these residues in the transition state. 
 
Figure 8. The active site of the RasGAP•Ras•GDP•AlF3 complex showing important elements 
of catalysis (from Scheffzek et al., 1997).  
 
2.2.2 RhoGAPs 
Numerous GAPs specific for Rho/Rac/Cdc42 have been described and several 
structures have been solved (Barrett et al., 1997; Rittinger et al., 1997a; Rittinger et 
al., 1997b; Nassar et al., 1998). Similar to GAPs for Ras, these proteins are purely 
helical (Figure 9). Based on their similar three-dimensional architecture, it was 
proposed that RhoGAPs and RasGAPs have a common evolutionary origin although 
no obvious sequence similarity is observed (Rittinger et al., 1998).  
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The structure of the RhoGAP•Rho•GDP•AlF3 complex revealed that the mechanism 
of GTPase stimulation involves - as in the case of RasGAP – the introduction of a 
catalytic arginine from the GAP and stabilisation of the catalytic glutamine in Rho 
(Rittinger et al., 1997b).   
 
Figure 9. Structure of RhoGAP in complex with Rho•GDP•AlF −4  (PDB accession code 1AM4). 
RhoGAP is in coloured in red, Rho in orange and blue.  
 
2.2.3 Gα proteins and regulators of G protein signalling  
Gα proteins transduce signals from seven-helix-transmembrane receptors to 
downstream targets. The crystal structure of Gαtα in the GTPγS bound state showed 
that these proteins have a Ras-like G domain fold with a helical insertion shortly 
behind the switch I region (Noel et al., 1993). The structure of a Gα protein bound to 
GDP and aluminium fluoride revealed that the mechanism of GTP hydrolysis involves 
stabilisation of the attacking water molecule by a catalytic glutamine (homologous to 
glutamine Q61 in Ras) and by a threonine from the helical domain (Coleman et al., 
1994). Strikingly, the GTPase reaction was highly dependent on an arginine residue 
supplied by the helical domain which makes a hydrogen bond to aluminium fluoride 
mimicking the transition state of GTP hydrolysis. This arginine residue provided by 
Gα in cis (from Gα itself) is the functional equivalent of the arginine finger of RasGAP 
and RhoGAP which is provided in trans (from a second molecule).  
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Regulator of G protein signalling (RGS) proteins accelerate the intrinsic reaction of 
Gα proteins but do not share sequence homology to any other GAPs (Druey et al., 
1996). They bind with modest affinity to the GTP bound forms of Gα and with high 
affinity to the GDP•AlF −4
 bound form and stimulate GTP hydrolysis by at least 50-fold. 
The structure of RGS4 bound to Giα1•GDP•AlF −4
 showed that RGS proteins are 
helical, bind to the switch regions of Gα and stabilise them (Figure 10; Tesmer et al., 
1997). However, they do not contribute catalytic residues to the active site of Gα 
except one asparagine residue which stabilises the catalytic glutamine of Gα. It was 
suggested that this asparagine could assist in the positioning of the hydrolytic water 
molecule.  
 
  
Figure 10. Complex structure of RGS4 bound to Giα1•GDP•AlF −4 (PDB code 1AGR). Giα1 is 
shown in orange and blue, its helical insert domain in purple and RGS4 in red.  
 
2.2.4 Other GAPs with an arginine finger  
RabGAPs comprise a family of GAPs for the small GNBP Rab (Ypt in yeast) involved 
in vesicle trafficking. The structure of the yeast GAP Gyp1 revealed a fully α-helical 
protein (Figure 11A) albeit with a different fold than GAPs for Ras, Rho and Gα 
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proteins (Rak et al., 2000). By mutational analysis, an arginine was identified which is 
critical for the catalytic activity (Albert et al., 1999). However, the exact mode of 
interaction between RabGAP and Rab is currently unknown, since no structure of a 
RabGAP-Rab complex has been described yet. 
Some bacterial toxins such as ExoS from Pseudomonas aeruginosa, SptP from 
S. typhimurium and YopE from Yersinia sp. are introduced in eukaryotic cells and act 
as Rho-specific GAPs to reorganise the cell’s cytoskeleton (Goehring et al., 1999;  
Fu and Galan, 1999; Pawel-Rammingen et al., 2000). The structure of the GAP 
domain of ExoS (130 residues, from here on ExoS) in complex with Rac•GDP•AlF −4  
was solved (Figure 11B; Wurtele et al., 2001). It revealed that ExoS has a helical fold 
with a small two-stranded β-sheet. No structural homology was observed to any other 
known GAP structure. However, the mechanism of GTPase stimulation is similar to 
other GAPs since ExoS also provides an arginine finger into the active site of Rac. 
Similarly, the structure of SptP in complex with Rac1•GDP•AlF3 revealed that SptP 
provides a catalytic arginine to Rac1 (Stebbins and Galan, 2000). It was suggested 
that bacterial GAPs and RhoGAPs have most likely evolved independently. 
 
Figure 11. A) Ypt GAP (PDB code 1FKM) is a purely helical protein with no structural homology 
to other GAPs.   B) The GAP domain of ExoS (in red and green) in complex with 
Rac•GDP•AlF −4  (orange and blue) (PDB code 1HE1).   
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2.2.5 ArfGAP 
Arf is a small GNBP which is involved in vesicle trafficking in eukaryotic cells (for 
review see Spang, 2002). Arf in the GDP bound state translocates from the cytosol to 
the membrane and is activated by Arf specific exchange factors (Renault et al., 
2003). Arf in its GTP bound form associates with the membrane and recruits a seven-
subunit complex called coatomer. This process is followed by budding of a vesicle 
containing Arf and the coatomer complex. When the membrane curvature of the 
vesicle increases, the activity of ArfGAP also present in this complex is stimulated 
dramatically, leading to GTP hydrolysis and Arf•GDP dissociation (Bigay et al., 2003).  
The catalytic domain of the ArfGAPs family comprises 140 residues including a zinc 
finger motif (Cukierman et al., 1995). The structure of the ArfGAP domain including 
four C-terminal ankyrin repeats (Mandiyan et al., 1999) and of the ArfGAP domain in 
complex with Arf•GDP (Goldberg, 1999) was solved. It revealed that the zinc finger of 
ArfGAP – consisting of four strands and one helix – is embedded in an irregular array 
of six α-helices and one β-strand (Figure 12). Clearly, no structural similarity to any 
GAPs of another GNBP family was observed. 
 
Figure 12. Crystal structure of ArfGAP (in red and green) in complex with Arf•GDP coloured in 
orange and blue (pdb coordinates provided by J.Goldberg). ArfGAP binds to Arf at a 
position far away from the nucleotide binding site. 
Mutagenesis studies in ArfGAP revealed an arginine residue whose mutation to 
alanine dramatically reduced the GAP activity (Mandiyan et al., 1999). However, the 
structure of the complex showed that ArfGAP binds to a region of switch II of Arf 
which is at least 15 Å away from the nucleotide binding site. It was therefore 
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proposed that the GTPase reaction is not stimulated by a catalytic residue but rather 
by rearranging switch II of Arf leading to a better positioning of the catalytic glutamine 
in switch II. In further experiments it was shown, that upon addition of coatomer to 
Arf•GTP and ArfGAP, the GTPase reaction was a further 1000-fold stimulated. This 
suggests that the coatomer itself is involved in the GAP reaction and that an arginine 
finger is provided by the coatomer (Goldberg, 1999). 
Sar1 is an Arf related protein which is involved in the formation of so-called COPII 
coated vesicles on the endoplasmic reticulum (Pasqualato et al., 2002). COPII 
consists of Sar1 and two large heterodimeric complexes Sec23/24 and Sec13/31 
(Barlowe et al., 1994).  
Sar1 has a histidine residue at the equivalent position of the catalytic glutamine in 
most other small GNBPs, and the intrinsic GTP hydrolysis of Sar1 is very slow. 
However, GTP hydrolysis can be stimulated by the Sec23 subunit which does not 
show sequence similarity to other GAPs (Yoshihisa et al., 1993). The crystal structure 
of Sec23 in complex with Sar1•GppNHp revealed that Sec23 provides a catalytic 
arginine into the active site of Sar1, and that the catalytic histidine of Sar1 positions 
the attacking water molecule (Bi et al., 2002). This reaction employing a catalytic 
histidine for positioning of the attacking water is unique for small GNBPs but might be 
similar for EF-Tu (Cool and Parmeggiani, 1991; Berchtold et al., 1993; Vogeley et al., 
2001; Mohr et al., 2002). 
 
2.2.6 RanGAP – catalysis without an arginine finger 
RanGAPs stimulate the GTPase reaction of the small GNBP Ran (Seewald et al., 
2002) which is involved in nuclear transport. A third protein, RanBP, binds to Ran and 
increases its affinity for RanGAP (Seewald et al., 2003). RanGAPs consist of a 
modular architecture with a 330-350 residue leucine-rich repeat (LRR) domain 
followed by an acidic region of approximately 40 residues (Hillig et al., 1999). The 
LRRs appear in proteins with various function, e.g. in the ribonuclease A inhibitor or 
Drosophila Toll-like receptor (Kobe and Deisenhofer, 1995). A single LRR forms a 
β-α hairpin consisting of a β-strand, a loop and an α-helix roughly parallel to the 
β-strand. The structure of yeast RanGAP showed that eleven LRR repeats form a 
crescent shaped molecule (Hillig et al., 1999). RanGAP does not have any structural 
similarity to the purely helical GAPs of Ras and Rho.  
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The complex between RanGAP, RanBP and Ran in the presence of a GTP analogue 
and in the presence of GDP and aluminium fluoride was solved (Figure 13; Seewald 
et al., 2002). Surprisingly, the only arginine in the vicinity of the active site was bent 
away from the γ-phosphate or the aluminium fluoride, and it was previously shown 
that this arginine is not important for catalysis (Hillig et al., 1999). This led to the 
proposal that RanGAP mediates GTP hydrolysis without an arginine finger. It was 
suggested that the basic machinery of fast GTP hydrolysis is provided exclusively by 
Ran and that binding of RanGAP leads to correct positioning of the catalytic 
glutamine in Ran. 
 
Figure 13. Structure of RanGAP in complex with Ran•GDP•AlF3 and RanBP1 (PDB code 1K5D). 
RanGAP is shown in green and red, Ran in yellow and blue and RanBP1 in purple. 
 
2.2.7 The signal recognition particle and its receptor 
The signal recognition particle (SRP) and its receptor (SR) target newly synthesised 
proteins destined for secretion or membrane integration to the endoplasmic reticulum 
(Keenan et al., 2001). Both SRP and SR are conserved across all kingdoms of life. In 
prokaryotes, SRP consists of a single 48 kD GTPase called Ffh and a 110 nucleotide 
4,5S RNA, whereas SR consists of the GTPase called FtsY. When both proteins are 
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loaded with GTP, they can bind to each other leading to a reciprocal stimulation of 
their GTPase activities, GTP hydrolysis and concomitant dissociation of the complex.  
Very recently, the mechanism of this reciprocal stimulation was elucidated by solving 
the structure of the complex between the two GTPases in the presence of a 
non-hydrolysable GTP analogue (Egea et al., 2004; Focia et al., 2004). The two 
GTPases form a quasi symmetric heterodimer, and the two nucleotides are aligned in 
a nearly symmetrical composite active site (Figure 14). In each chain, a catalytic 
aspartate was identified which is thought to activate the attacking nucleophilic water 
molecule in cis. Additionally, an arginine and a glutamine residue are provided from 
both molecules into the active site and interact in cis and possibly in trans with the β- 
and γ-phosphate groups. Strikingly, the 3’ OH group of each GTP molecule contacts 
the γ-phosphate group of the opposing GTP molecule and reduces the negative 
charge on the γ-phosphate. This hydroxyl group was shown to be essential for 
association, reciprocal activation and catalysis (Egea et al., 2004).  
 
Figure 14. Ribbon type presentation of the SRP and SR heterodimer both in the GppNHp bound 
form (PDB code 1OKK). The nucleotides are buried in a common active site. SRP is 
shown in green and red, SR in orange and blue. 
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2.3 GTPase activating proteins of the Rap1GAP family 
2.3.1 Rap1GAP  
Rap1GAP (formerly GAP3) was isolated as a soluble and a membrane-associated  
isoform from cytosolic brain extract (Kikuchi et al., 1989; Polakis et al., 1991) which 
specifically stimulate GTP hydrolysis in Rap1, and to a smaller extent in Rap2 
(Janoueix-Lerosey et al., 1992). The protein responsible for this activity was 
sequenced and the corresponding gene was cloned from a human brain cDNA 
(Rubinfeld et al., 1991). It turned out to encode a polypeptide of 663 amino acids with 
a molecular weight of 73 kD which in human is expressed most abundantly in brain, 
foetal tissue, undifferentiated cells and certain tumour cell lines. By deletion analysis 
it was shown that a protein fragment consisting of amino acids 75-416 is necessary 
and sufficient to retain full GAP activity (Rubinfeld et al., 1992). This fragment did not 
show any sequence similarity to GAPs of other small GNBPs. However, homologous 
sequences have been identified in the human genes Spa1 (Hattori et al., 1995), 
E6TP1/SpaR/SpaL (Gao et al., 1999; Roy et al., 1999) and Tsc2 (Figure 15; 
Tuberous Sclerosis Consortium,1993). Homologues of these genes are found in all 
higher organisms. 
Rap1GAP was shown to be regulated by protein degradation and relocalisation from 
cytosol to the membrane. It is phosphorylated in vivo at four distinct sites which are 
located C-terminally of the catalytic fragment (Polakis et al., 1992; Rubinfeld et al., 
1992). Recently, it was demonstrated that in thyroid cells phosphorylation of 
Rap1GAP by GSK3β is associated with proteasome-mediated degradation 
(Tsygankova et al., 2004). 
A splice isoform of Rap1GAP, RapGAPII, is expressed in heart, liver, kidney and 
cerebrum and contains an N-terminal GoLoco motif which specifically binds to the 
α-subunits of the Gi family of heterotrimeric G-proteins (Mochizuki et al., 1999; 
Kimple et al., 2002). Upon stimulation of Gi, RapGAPII translocates from the cytosol 
to the membrane, followed by a decrease of Rap1•GTP and an activation of the ERK 
pathway, thus linking Gi and Rap1 signalling pathways. Rap1GAP was also shown to 
bind to the GTP bound form of Gαz (Meng et al., 1999) accompanied by a decrease 
of cellular Rap1•GTP (Meng and Casey, 2002) and to the GDP bound form of Gα0 
accompanied by an increase of cellular Rap1•GTP (Jordan et al., 1999).  
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Another possible interaction partner of Rap1GAP is the cytoskeleton-anchoring 
protein AF-6 (Su et al., 2003) which was earlier described as a putative Rap1 effector 
(Linnemann et al., 1999; Boettner et al., 2000). It was proposed that the interaction is 
mediated by the PDZ domain of AF-6 which should bind to an internal VVF motif of 
Rap1GAP located in the catalytic domain (Su et al., 2003).  
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Figure 15. Schematical view of the Rap1GAP family showing the domain structure of the 
involved proteins. Abbreviations used here:  CC: coiled coil,  Act: actin regulatory 
domain,  GKBD: guanylate kinase-like binding domain, TAD: Transcription 
activation domain  CAM: Calmoduline binding domain. The GoLoco domain is 
present in RapGAPII but not Rap1GAP. This figure was kindly provided 
by P. Chakrabarti. 
  
2.3.2 Signal-induced proliferation-associated protein 1 (Spa-1) 
Spa-1 encoding a 130 kD protein was identified as a gene which was little expressed 
in a quiescent murine lymphoid cell line but was induced upon interleukin-2 
stimulation (Hattori et al., 1995). The corresponding protein contains the Rap1GAP 
domain, a PDZ domain involved in protein-protein interaction and a C-terminally 
located coiled-coil region (Figure 15). In human, Spa-1 is most abundantly expressed 
in lymphoid tissues such as thymus, spleen but not in tissues expressing Rap1GAP 
such as brain, kidney and pancreas (Kurachi et al., 1997). Baculo-virus expressed 
Spa-1 showed specific GAP activity towards Rap1 and Rap2 (Kurachi et al., 1997). 
As for Rap1GAP, AF-6 was described as possible interaction partner (Su et al., 
2003). Recently, Spa-1 was shown to be a tumour-suppressor gene since Spa-1 
knockout mice developed a spectrum of myeloid disorders that resembled human 
chronic myelogenous leukaemia (Ishida et al., 2003). Furthermore, it was 
demonstrated that the increased Rap1•GTP levels caused by Spa-1 deletion were 
responsible for increased cell proliferation of hematopoietic progenitors. 
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2.3.3 E6TP-1 
E6TP1 (E6 targeted protein 1) was identified as a 200 kD protein which is targeted to 
proteasome-mediated degradation by the papilloma virus protein E6 (Gao et al., 
1999). Degradation of E6TP1 was correlated with the ability of E6 to immortalise 
mammary epithelial cells (Gao et al., 2001a), thus establishing the role of E6TP1 as a 
tumour suppressor gene. The 1804 residue protein is widely expressed in tissues 
and in-vitro cultured cell lines. Like Spa-1, it contains a Rap1GAP homology domain 
(residues 489–819), a PDZ domain and a coiled-coil region (Figure 15). Additionally, 
it has two actin binding domains (Pak et al., 2001). GAP activity towards Rap1 and 
Rap2 was demonstrated (Singh et al., 2003). 
SPAR/SPAL is the rat homologue of E6TP1 and was found to form a complex with 
PSD-95 and NMDA receptors in neurons. This complex has a crucial role for 
establishing dendritic spines (Pak et al., 2001) which are postsynaptic protrusions 
where glutamate-mediated neuronal transmission takes place (Meyer and Brose, 
2003). Phosphorylation of SPAR1 by serum-inducible kinase leads to its degradation 
accompanied by loss of the dendritic spine (Pak and Sheng, 2003). Thus, SPAR is a 
critical component in the formation of neuronal activity albeit the role of Rap1 
regulation is unclear to date.   
 
2.3.4 Tuberin 
Tuberous sclerosis (Tsc) is an autosomal dominant inherited disease with a 
prevalence of 1 in 6000 births characterised by benign tumours called hamartomas in 
a variety of tissues, as well as rare malignancies (reviewed in Manning and Cantley, 
2003; Li et al., 2004). Other symptoms include mental retardation and epilepsy. This 
disease is caused by loss of function mutations in either of the two tumour 
suppressor genes Tsc1 and Tsc2 encoding Hamartin (130 kD) and Tuberin (200 kD), 
respectively (Tuberous Sclerosis Consortium, 1993; van Slegtenhorst et al., 1998). In 
vivo, Tuberin and Hamartin form a heterodimer which is thought to stabilise the two 
proteins. This complex functions in the insulin/mTOR pathway to inhibit cell growth 
and proliferation (Potter et al., 2002; Tee et al., 2002). 
Tuberin was shown to have sequence homology to a C-terminal fragment of the 
Rap1GAP domain, and in-vitro GAP activity towards the small GNBPs Rap1 and 
Rab5 was reported (Wienecke et al., 1995; Xiao et al., 1997). However, it is evident 
now that Tuberin acts in vivo as a GAP towards the small GNBP RheB (Tee et al., 
Introduction 
25 
2003; Garami et al., 2003; Castro et al., 2003; Zhang et al., 2003). It is currently 
unclear how RheB in the GTP bound form can activate the downstream effector 
kinase mTOR.   
 
2.3.5 Biochemistry of the Rap1-Rap1GAP system 
A catalytic glutamine (glutamine Q61 in Ras) is crucial for the intrinsic and GAP 
stimulated GTP hydrolysis of Gα, Ras, Rho, Rab and Ran GNBPs. In contrast, Rap1 
does not have a catalytic glutamine but a threonine at the equivalent position. As a 
result, the intrinsic GTP hydrolysis rate of Rap1 is 10-fold slower than for Ras but can 
be reconstituted by exchanging threonine T61 for a glutamine (Frech et al., 1990). 
Furthermore, threonine T61 is not required for the intrinsic and GAP stimulated GTP 
hydrolysis in Rap1 (Maruta et al., 1991). It is therefore anticipated that the 
mechanism of hydrolysis is different between Rap1 and the other GNBPs. 
Glycine G12 mutations in Ras and other GNBPs render the protein inactive to GAPs 
since any side-chain at position 12 would interfere with the positioning of the arginine 
finger and the catalytic glutamine (see above). However, the G12V mutant of Rap1 
can still be down-regulated by Rap1GAP, albeit with an 8-fold reduced rate 
(Brinkmann et al., 2002). This again indicates that Rap1GAP stimulates GTP 
hydrolysis in a completely different way than all other GAPs. 
A fluorescence assay was developed to monitor a single turnover reaction cycle of 
the Rap1GAP catalysed reaction in Rap1 (Kraemer et al., 2002). It was proposed that 
the rate limiting step of the reaction was not GTP hydrolysis but the release of 
inorganic phosphate, similarly as already proposed for RasGAP-Ras system (Allin et 
al., 2001).   
 
Introduction 
26 
2.4 Objectives of this work 
All available data indicated that the Rap1GAP stimulated reaction is fundamentally 
different from all other GAP systems described hitherto (see above). Therefore, this 
new mechanism was explored by biochemical and structural analysis.  
In a first step, the reaction should be characterised and residues important for 
catalysis should be identified. Consequently, the structure of one member of the 
Rap1GAP family should be solved. It was expected that Rap1GAP has a completely 
novel GAP fold since no sequence similarities to any other GAP could be detected. 
Based on the structure and the available biochemical data, the catalytic centre 
should be identified and further characterised by mutational and biochemical analysis.  
This work also aimed to understand the molecular basis for diseases such as 
Tuberous sclerosis since single point mutations in the Rap1GAP domain of Tuberin 
were described in Tuberous sclerosis patients. However, the role of these mutations 
in disease was unclear and could be unravelled by understanding the involved 
reaction mechanism. 
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3 Materials and Methods 
3.1 Materials 
3.1.1 Chemicals 
Chemicals from the following companies were used: Amersham-Pharmacia 
(Freiburg), Baker (Deventer, Niederlande), Fluka (Neu-Ulm), GERBU (Gaiberg), 
Merck (Darmstadt), Pharma-Waldhof (Düsseldorf), Qiagen (Hilden), Riedel-de-Haen 
(Seelze), Roche (Mannheim), Roth (Karlsruhe), Serva (Heidelberg) und Sigma-
Aldrich (Deisenhofen). 
 
3.1.2 Enzymes 
DNAase-I     Roche (Mannheim) 
Pfu DNA polymerase   New England Biolabs (Schwalbach) 
Restriction enzymes   New England Biolabs (Schwalbach) 
T4 DNA ligase    New England Biolabs (Schwalbach) 
Trypsin, α-chymotrypsin   Sigma (Deisenhofen) 
Thrombin     Serva (Heidelberg) 
 
3.1.3 Kits 
QIAprep Spin Miniprep Kit   Qiagen (Hilden) 
QIAquick Gel Extraction Kit  Qiagen (Hilden)  
BigDye Terminator Sequencing Kit Applied Biosystems (Langen) 
λ-DNA standard    Invitrogen (Karlsruhe) 
Wide Range, SDS7 protein marker Sigma  (Deisenhofen) 
 
3.1.4 Microorganisms 
E. coli CK600K  supE, hsdM+, hsdR-, kanR (Hoffmann-Berling, Heidelberg) 
 
E. coli TG1 K12, supE, hsd∆5, thi, ∆(lac-proAB), F’[traD36, proAB+, lacIq, 
lacZ∆M15] (Promega) 
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E. coli BL21 (DE3) B, F-, hsdSB (rB-, mB-), gal, dcm, ompT, λ(DE3) (Novagen)  
 
E.coli BL21 (DE3)  F–  ompT hsdSB(rB– mB–) gal dcm (DE3) pRARE2 (CmR) 
Rosetta (Novagen) pRARE containing the tRNA genes argU, argW, 
ileX, glyT, leuW, proL, metT, thrT, tyrU, and thru 
 
3.1.5 Media and antibiotics 
Luria-Bertani (LB) 10 g/l Bactotryptone, 10 g/l NaCl, 5 mM NaOH, 5 g/l yeast extract  
 
Terrific Broth (TB)  12 g/l BactoTryptone, 24 g/l Bacto-yeast-extract, 4 g/l glycerol, 
17 mM KH2PO4, 72 mM K2HPO4  
 
Standard I  25 g/l standard-I powder (Merck, Darmstadt) 
 
SeMet-Medium was prepared according to Van Duyne et al. (1993). It is a minimal 
medium which contains 50 mg/l seleno-L-methionine (Calbiochem-Novabiochem, 
Schwalbach), no methionine, a high concentration (250 mg/l) of the amino acids Val, 
Leu, Ile, Lys, Thr, Phe to suppress bacterial methionine biosynthesis and 50 mg/ml of 
the other amino acids. 
 
Antibiotics from GERBU (Gaiberg) were used in the concentration 100 mg/l. 
  
3.1.6 Buffers 
PBS  140 mM NaCl; 2,7 mM KCl; 10,1 mM Na2HPO4; 1,8 mM KH2PO4 
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3.2 Molecular biology methods  
3.2.1 Agarose gels 
Agarose gels were prepared and run according to standard procedures (Sambrook, 
1989). 
 
3.2.2 Isolation of plasmid DNA 
DNA was isolated using QIAprep Spin Miniprep Kit from Qiagen (Hilden) according to 
the manufacturer’s protocol.  
 
3.2.3 Polymerase chain reaction (PCR) 
Amplification of DNA fragments was carried out using Pfu polymerase (New England 
Biolabs, Schwalbach) or Pwo polymerase (Roche, Mannheim) according to standard 
procedures (Sambrook, 1989). Fragments were digested (see 3.2.3) and purified 
using QIAquick Gel Extraction Kit (Hilden) according to the manufacturer’s protocol.   
 
3.2.4 DNA digestion 
DNA was digested using enzymes from New England Biolabs (Schwalbach) 
according to the manufacturer’s protocol. 
 
3.2.5 Ligation 
Vector and insert DNA were quantified in agarose gels using digested λ-marker (New 
England Biolabs, Schwalbach) as a reference. 10 ng of vector was ligated with a six 
fold molar excess of insert overnight at 8 °C using T4 ligase (Roche, Mannheim) 
according to the manufacturer’s protocol. 
 
3.2.6 Competent cells 
Competent cells were prepared according to Chung et al. (1989). 200 ml LB medium 
was inoculated with 2 ml preculture and grown at 37 °C until an OD600 of 0,4. 
Bacteria were incubated for 20 min on ice, pelleted for 5 min at 1200 x g (4 °C), 
resuspended in 20 ml ice-cold sterile TSS buffer (85% LB medium without NaOH, 
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10% PEG 8000, 5% DMSO, 50 mM MgCl2, pH 6,5), flash frozen and stored 
at -80 °C.   
 
3.2.7 Transformation 
The heat shock method was used according to the standard protocol (Sambrook, 
1989). Ligated DNA was transformed in E. coli TG-1, amplified and isolated. The 
isolated DNA was transformed in BL21 (DE3) expression bacteria.    
 
3.2.8 Bacteria storage 
30% glycerol was added to an overnight culture and bacteria stocks were stored 
at -80 °C.  
 
3.2.9 Site specific mutagenesis 
Site specific mutagenesis was carried out using the QuickChange kit (Stratagene, 
Amsterdam) according to the manufacturer’s protocol. 
 
3.2.10 DNA sequencing 
DNA sequencing was done according to Sanger et al. (1992) using the Big Dye 
terminator kit (Applied Biosystems, Langen). A sequencing reaction contained 10 µl 
DNA Qiaprep solution (see 3.2.2), 4 µl terminator mix, 3 pmol sequencing primer in a 
volume of 20 µl. The sequencing PCR and DNA precipitation was carried out 
according to the manufacturer’s protocol. Analysis of the sequencing products was 
done in house on a ABI PRISM 3700 DNA Analyzer (Applied Biosystems, Langen). 
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3.2.11 Constructs 
Construct Remark 
ptac Rap1B C’1-166 Provided by D. Kühlmann 
pGEX 4T1 hsRap1GAP75-415 
Provided by P. Stege, expressed protein soluble and 
active 
pGEX 4T1 hsRap1GAP86-405 Expressed GST-fusion not cleavable by thrombin 
pGEX 4T1 hsRap1GAP75-405 
Expressed protein prepared in big amounts, initial 
crystallisation trials 
pGEX 4T1 hsRap1GAP178-405 Expressed protein insoluble 
pGEX 4T1 hsRap1GAP188-388 
Provided by D. Kühlmann, expressed protein 
precipitated upon removal of GST 
pGEX 4T1 hsRap1GAP183-398 
Expressed protein could be prepared and GST 
cleaved in big amounts 
pGEX 4T1 hsRap1GAP171-405 Expressed protein insoluble 
pGEX 4T1 dmRap1GAP234-541 
Expressed GST-fusion soluble but precipitated upon 
removal of GST 
pGEX 4T1 dmRap1GAP215-555 Expressed protein insoluble 
pGEX 4T1 dmRap1GAP234-541 Expressed protein insoluble 
pGEX 4T1 dmRap1GAP234-555 Expressed protein insoluble 
pGEX 4T1 dmRap1GAP215-541 Expressed protein insoluble 
pGEX 4T1 dmRap1GAP343-555 Expressed protein insoluble 
pGEX 4T1 dmRap1GAP343-541 Expressed protein insoluble 
pGEX 4T1 dicRap1GAP913-1212 Provided by Dr. Faix, expressed protein insoluble 
pGEX 4T1 hsSpa-1205–557 Expressed protein insoluble 
pGEX 4T1 hsSpa-1205–549 Expressed protein insoluble 
pGEX 4T1 hsE6TP1485-824 Expressed protein insoluble 
pGEX 4T1 hsE6TP1477-824 Expressed protein insoluble 
pGEX 4T1 hsTuberin1208-1784 
Provided by Eva Kostinova, expressed protein 
degraded upon purification 
pGEX 4T1 hsTuberin1346-1784 
Provided by Eva Kostinova, expressed protein 
degraded upon purification 
pGEX 4T1 hsTuberin1532-1760 Expressed protein degraded upon purification 
pGEX 4T1 hsTuberin1498-1760 Expressed protein degraded upon purification 
 
3.2.12 Point mutants 
Construct Point Mutants 
pGEX4T1 Rap1GAP75-415 Wild-type, R91A, R128A, R132A, K194A, R286A,  Q204A, R388A were provided by P. Stege 
pGEX4T1 Rap1GAP75-415  (F100E, L173E), E207A, R240A,  H267A, H287A, N290A, N290I, N290K, D291A, F313A, R339A 
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3.3 Biochemical methods 
3.3.1 Sequence alignment 
Sequences were aligned using the ClustalW algorithm (Thompson et al., 1994) and 
manually refined using Genedoc (Nicholas et al., 1997). 
  
3.3.2 SDS-PAGE 
Separation of proteins of different molecular weight was performed according to 
Laemmli (1970) using denaturing, discontinuous SDS-polyacrylamide gel 
electrophoresis (SDS-PAGE). 
 
3.3.3 Determination of protein concentration 
Protein concentration was determined according to Bradford (1976) using the Biorad 
protein assay (Biorad). The solution was calibrated using bovine serum albumin. 
 
3.3.4 Matrix assisted laser desorption ionisation (MALDI) 
The molecular weight of newly isolated proteins, digested protein bands and heavy 
atom protein derivatives was determined by matrix assisted laser desorption 
ionisation (MALDI). A concentrated protein solution was diluted with water and 1:1 
mixed with matrix (for proteins > 10 kD: saturated sinapinic acid in acetonitrile, 
0,2% TFA; for peptides < 10 kD: saturated a-cyano-4-hydroxy cinnamic acid in 
acetonitrile, 0,2% TFA water). Data were acquired on a Voyager DE Pro (Applied 
Biosystems). 
 
3.3.5 Test expression 
To test expression and solubility of proteins expressed from pGEX vectors, vectors 
containing the desired insert were transformed in expression bacteria (BL21-DE3 and 
BL21-DE3 Rosetta). A 50 ml bacteria culture in TB medium was induced at on OD600 
of ~0,4 with 500 µM IPTG and grown at 37 °C overnight. Two other cultures were 
induced with 50 µM and 200 µM IPTG and grown at 18 °C overnight.   
To test expression, 1 ml of the overnight culture was pelleted, resuspended in water 
and analysed using SDS-PAGE. To test the solubility, 1 ml bacteria culture was 
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pelleted, resuspended in 100 µl BugBuster solution (Novagen) and lysed for 5 min on 
ice. The solution was centrifuged at 25000 X g for 10 min at 4 °C. Fractions of 5 and 
10 µl of the supernatant were analysed by SDS-PAGE. Alternatively, 20 ml bacteria 
were pelleted and resuspended in 1 ml buffer of choice. Cells were broken by 1 min 
sonification on ice using a Sonifier 450 (Branson Ultrasonics, Danburry, USA) at 50% 
duty cycle. After 30 min centrifugation at 4 °C and 25000 x g, various amounts of the 
supernatant were analysed via SDS-PAGE.  
  
3.3.6 Protein overexpression and preparation of soluble bacteria extract  
Proteins were overexpressed using the parameters described in Table 1. 
 
Table 1 Expression constructs and expression conditions 
Plasmid E.coli strain Medium Antibiotics 
Induction 
at OD600 
[IPTG] 
/ µM 
T / 
°C 
Expression 
time / h 
Ptac Rap1B C’ CK600K Standard I Amp, Kan 0,8 500 30 24 
pGEX4T1 Rap1GAP Bl21DE3 TB Amp 0,2 50 18 24 
pGEX4T1 Rap1GAP 
SeMet Bl21DE3 
SeMet 
medium Amp 0,2 50 18 48 
All other pGEX 
vectors Bl21DE3 TB Amp 0,2 50 18 24 
 
Upon expression, bacteria were pelleted at 4000 x g, resuspended in buffer 
containing 100 µM phenylmethylsulfonylfluoride (PMSF) as protease inhibitor and 
frozen at -20 °C. Cells were thawn, 20 mg/l DNase I (stock 20 g/l in 1 M MgCl2) and 
100 µM PMSF was added and the cells incubated for 30 min on ice. Cells were 
broken using a micro fluidizer (Microfluidics, Newton, USA). Insoluble material was 
removed by centrifuging at 100.000 x g for 45 min, and the supernatant used for 
further purification. 
 
3.3.7 Rap1GAP purification 
Rap1GAP75-415, selenomethionine substituted Rap1GAP75-415, Rap1GAP75-410 and all 
Rap1GAP mutants were purified as GST-fusion according to Brinkmann et al. (2002) 
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with a subsequent gel filtration. The first buffers contain ATP, potassium and 
magnesium ions to remove bound GroEL. 
Bacteria were broken in PBS, 5 mM MgCl2, 5 mM DTE, 1 mM ATP, 100 µM PMSF 
(see 3.3.5). The cell supernatant was applied to a GST-column (25 ml, Amersham, 
Freiburg) equilibrated with PBS, 5 mM MgCl2, 5 mM DTE, 1 mM ATP and 
excessively washed with at least 500 ml of the same buffer. The buffer was 
exchanged to PBS, 5 mM DTE or 50 mM Hepes (pH 7,5), 100 NaCl, 2 mM CaCl2, 
5 mM DTE. GST was cleaved by addition of 300 units thrombin (Serva) and overnight 
incubation. Rap1GAP was eluted with PBS, 5 mM DTE or 50 mM Hepes (pH 7,5), 
100 NaCl, 2 mM CaCl2, 5 mM DTE. The protein was concentrated (30 mg/ml) using 
an Amicon concentrator (10 kD cutoff) and further purified on a Sephadex200 gel 
filtration using 20 mM Hepes (pH 7,5), 100 mM NaCl, 5 mM DTE as running buffer. 
Rap1GAP eluted in two peaks from gel filtration, the first one containing bound 
chaperone and eluting in the exclusion volume, the second eluting as protein with an 
apparent molecular weight of 100 kD and containing pure Rap1GAP. Protein from the 
second peak was pooled, concentrated and twice washed with 20 mM Hepes 
(pH 7,5), 5 mM DTE using Amicon concentrators (10 kD cutoff) to remove NaCl. The 
protein was finally concentrated to 60 mg/ml and flash frozen. 
 
3.3.8 Purification of other GST fusion proteins 
All GST-fusions were prepared as described in 3.3.7 with the following modification.  
The running buffer was 50 mM Hepes (pH 7,5), 100 mM NaCl, 5 mM DTE. GST was 
cleaved in 50 mM Hepes (pH 7,5), 100 mM NaCl, 5 mM DTE, 2 mM CaCl2. 
 
3.3.9 Assignment of degradation bands 
Rap1GAP75-415 and Rap1GAP75-405 showed specific degradation bands after 
incubation for few days at 8 °C.  
To locate these fragments, peptide masses were determined by MALDI (3.3.4). 
Rap1GAP75-415 yielded fragments of 24,4 kD and 14,4 kD mass adding up to the mass 
of 39 kD of Rap1GAP. Rap1GAP75-405 yielded fragments of 23,4 kD and 14,4 kD 
mass indicating that the 24,4 kD fragment is C-terminally located. 
 
Materials and Methods 
35 
3.3.10 Partial digest 
Rap1GAP was partially digested to find a smaller, compact folded Rap1GAP 
fragment. The reaction buffer was chosen according to the protease employed 
(Table 2). The reaction (100 µl) containing 100 µg Rap1GAP was started at 20 °C by 
adding the indicated amount of protease. After 0 min, 5 min, 10 min, 15 min, 20 min, 
30 min, 60 min, 120 min, 240 min and 1000 min, 10 µl aliquots were transferred in 
SDS sample buffer and immediately flash frozen. Aliquots were analysed by SDS-
PAGE. Tested proteases are depicted in Table 2.  
 
Table 2 Proteases with the chosen reaction buffer. 
 
3.3.11 Purification of Rap1B C’ 
C-terminally truncated Rap1B (Rap1B C’) was purified according to 
Tucker et al. (1986). Bacteria were broken in 32 mM Tris (pH 7,5), 100 µM PMSF, 
2 mM EDTA (see 3.3.6).  
The cell supernatant was applied on a Q-sepharose column equilibrated with 
0,5 x buffer C. The column was excessively washed with 0,5 x buffer C and bound 
proteins were eluted using a salt gradient (0-300 mM NaCl) in 0,5 x buffer C. 
Fractions containing Rap1B C’ were identified using SDS-PAGE and pooled. Protein 
was precipitated by slowly adding solid ammonium sulfate (3M final concentration). 
Precipitated protein was pelleted by centrifugation for 60 min at 16000 x g and 
resuspended in buffer D. Rap1B C’ was further purified on a Sephadex75 gel 
filtration column equilibrated with buffer D. Fractions containing Rap1B C’ were 
pooled and concentrated using an Amicon concentrator (10kD cutoff).    
 
Buffer C  64 mM Tris, 10 mM MgCl2, pH 7,6 (HCl), 5 mM DTE  
Buffer D    1 x Puffer C, 200 µM GDP, 0,4 M NaCl, 5 mM DTE 
Protease Reaction buffer Final conc. Temp 
α-Chymotrypsin 50 mM Tris (pH 8) 8 µg / ml 25 °C 
Trypsin 50 mM Tris (pH 8) 2 µg / ml 15 °C 
Aminopeptidase 50 mM Tris (pH 8) 3 µg / ml 25 °C 
Carboxypeptidase 50 mM Tris, 50 µM ZnCl2 pH 6,5 4 µg / ml 30 °C 
Elastase 50 mM Tris (pH 8,9) 8 µg / ml 30 °C 
Papain 50 mM MES, pH 6,5 4 µg / ml 25 °C 
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3.3.12 Rap1-Aedans preparation 
Rap1-Aedans•GTP wild-type was a gift of Astrid Krämer and was prepared according 
to Kraemer et al. (2002). Rap1-AedansT61Q was a gift of Partha Chakrabarti. In this 
method, a surface-exposed cysteine is modified by a haloacetamides (here 
1,5-Iaedans) which is an environmentally sensitive fluorophore and acts as an 
indicator of protein binding. 
The Rap1B C’A86C and Rap1B C’A86C,T61Q mutants were prepared as described in 
3.3.11. DTE interferes with the labelling reaction. Thus, DTE was exchanged with a 
buffer containing 2 mM ascorbate using ultrafiltration with an Amicon concentrator 
(10 kD cutoff). The protein was diluted to 100 µM and incubated with a 3-fold excess 
of 1,5-Iaedans for 12 h at 4 °C. The reaction was stopped by buffer exchange with 
standard buffer containing DTE. Products were analysed by mass spectrometry. The 
protein was flash frozen and stored at -80 °C. 
 
3.3.13 Nucleotide exchange 
Nucleotide exchange was performed according to Tucker et al. (1986). This method 
uses EDTA which binds Mg2+ ions leading to an increase in the dissociation rate of 
the nucleotide. The nucleotide can then be exchanged by an excess of freshly added 
nucleotide.   
200 µM Rap1B C’ in 50 mM Hepes (pH 7,5), 100 mM NaCl was incubated with 
15 mM EDTA, 150 mM ammonium sulfate and 10 mM nucleotide (stock 100 mM 
nucleotide in 1 M Hepes, pH 7,5) for 60 min at room temperature or overnight  
at 4 °C. The exchange reaction was stopped by adding 30 mM MgCl2. Non-bound 
nucleotide was removed by washing the protein several times with an Amicon 
concentrator (10 kD cutoff) at 4 °C. To confirm successful nucleotide exchange, the 
nucleotide concentration was determined (see 3.3.14) and compared to the protein 
concentration (see 3.3.3). The protein was flash frozen and stored at -80 °C. 
 
3.3.14 Nucleotide detection using reversed-phase HPLC 
This method was carried out according to Lenzen et al. (1995). The principle of 
nucleotide separation is the interaction between the hydrophobic static phase and the 
ion pair of nucleotide and tetrabutylammonium in the mobile phase. Depending on 
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the number of phosphates, a variable number of tetrabutylammonium ions are bound 
by the nucleotide which increases the retention time on the column.  
The sample was applied on a HPLC system Gold 166 (Beckman, Palo Alto, USA) 
and separated via a reversed-phase column ODS Hypersil C18 (Bischoff, Leonberg). 
Denatured proteins were adsorbed at a nucleosil-100-C18 precolumn. The running 
buffer contained 10 mM tetrabutylammoniumbromide, 100 mM potassium phosphate 
(pH 6,5) with 7,5% acetonitrile. Nucleotide peaks were detected by measuring 
adsorption at 254 nm and quantified by integration. The column was calibrated by 
standard nucleotide solutions.  
 
3.3.15 Radioactive charcoal assay 
This assay detects radioactive inorganic phosphate and was carried out according to 
Leupold et al. (1983). Charcoal is suspended in phosphoric acid and a reaction 
sample containing the GNBP loaded with [γ-32P] labelled GTP is added. The GNBP 
immediately denatures due to the acidic pH and binds with the nucleotide to the 
charcoal. Free radioactive phosphate will not bind since the charcoal is already 
saturated with phosphate. Upon removal of the charcoal by centrifugation, it can be 
quantified by scintillation counting. To determine initial rates of Rap1GAP stimulated 
GTP hydrolysis in Rap1, not more than 30% of Rap1•[γ-32P]GTP must have reacted.  
GTP was partially exchanged with [γ-32P]GTP by incubating 1,5 mM Rap1•GTP (see 
3.3.11) with 20 µCi of [γ-32P]GTP (800 Ci/mmol, Amersham-Pharmacia) in the 
presence of 12 mM EDTA for 30 min on ice. The exchange reaction was stopped by 
adding 25 mM MgCl2. 
Initial rates were determined using 100 nM Rap1GAP and increasing concentrations 
of Rap1•[γ-32P]GTP at 25 °C in standard buffer (here 30 mM Tris (pH 7,5), 
2 mM MgCl2, 5 mM DTE). At different time points, 10 µl aliquots of the reaction were 
withdrawn, added to 390 µl charcoal solution (5% (w/v) Norit in 20 mM H3PO4) and 
vortexed. To determine end points of GTP hydrolysis, all Rap1•GTP was hydrolysed 
by addition of a highly concentrated Rap1GAP solution, and a last aliquot was taken. 
Upon centrifugation, the radioactivity of a 200 µl aliquot of the charcoal supernatant 
was subjected to scintillation counting. Initial rates were evaluated by linear 
regression fitting, and Km and kcat were determined by fitting the initial rates to 
Michaelis-Menten equation using the program Grafit5 (Erythacus software). 
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3.3.16 Fast kinetics using stopped-flow measurement 
This method was carried out according to Kraemer et al. (2002) to examine fast 
reaction kinetics using an SX18MV-Stopped-flow-apparatus (Applied Photophysics, 
Leatherhead, U.K.). Dansylated protein was excited with monochromatic light 
(λ = 350 nm, band width = 6,4 nm) and emission was followed using a cut-off filter 
(λ > 408 nm). For every time course, 1000 data points were measured. 
 
3.3.16.1 Initial reaction assays 
The reaction buffer was 50 mM Hepes (pH 7,5), 100 mM NaCl, 5 mM MgCl2. 
2 µM Rap1-Aedans•GTP was 1:1 mixed with 50 µM Rap1GAP in a stopped-flow 
apparatus and the fluorescence was followed. All traces shown are the average of at 
least three (in most cases five) individual measurements.  
 
3.3.16.2 Displacement reaction 
The reaction buffer was 50 mM Hepes (pH 7,5), 100 mM NaCl, 5 mM MgCl2. 
2 µM Rap1-Aedans•GTP and 20 µM Rap1GAPN290A were mixed with 200 µM non-
labelled Rap1•GTP and the fluorescence monitored over 20 sec. 
 
3.3.16.3 AlF3 Binding assay  
Rap1-Aedans was incubated with a catalytic amount of Rap1GAP at 20 °C for 
120 min to convert it in the GDP bound form. For stopped-flow measurements, 
2 µM Rap1-Aedans•GDP in 50 mM Hepes (pH 7,5), 100 NaCl, 5 MgCl2, 
500 µM AlCl3, 5 mM NaF was rapidly mixed with 50 µM of the corresponding 
Rap1GAP construct and the fluorescence monitored over 500 sec.  
 
3.3.16.4 Data processing  
The fluorescence was normalised by dividing all data points by the initial value. To 
determine observed rate constants (kobs), individual traces were fitted to a 
monoexponential equation using the program Grafit 5 (Erithacus Software Limited). 
To determine association (kon) and dissociation (koff) rate constants, kobs rates were 
plotted against the Rap1GAP concentration and the data points fitted to a linear fit 
equation in which the slope corresponds to the kon and the intercept to the koff rate 
(see Appendix).  
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To determine the affinity constant by equilibrium titration, the maximal amplitudes of 
the kobs rate were plotted against the concentration of Rap1GAP and the data non-
linearly fitted (see Appendix). 
 
3.3.17 CD spectrometry 
CD spectra were taken at a Jasco J-710 CD Spectrometer (Japan Spectroscopic Co. 
Ltd., Tokyo, Japan) in a 100 µm quart cuvette with a band width of 1 nm, 1 nm step 
width, and 2 sec integration time. All spectra were 10 times accumulated. Data 
evaluation was done according to the Provenchor and Glockner method (Lobley et 
al., 2002)  
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3.4 Crystallographic methods  
3.4.1 Crystallisation 
For initial crystallisation trials, Rap1GAP was rapidly thawn and diluted to 20 mg/ml 
using 20 mM Hepes (pH 7,5), 5 mM DTE.  
All crystallisation trials were carried out using the hanging drop method. 1 ml of 
reservoir solution containing buffer, salt and precipitant was temperature equilibrated 
and put in 24-well cell culture linbro plate (Linbro, Flow Laboratories Inc., USA). The 
hanging drop consisted of 1 - 4 µl protein solution and 1 - 4 µl reservoir solution. 
Since Rap1GAP was very susceptible to protease impurities, all crystallisation trials 
were carried out at 4 °C and 12 °C. 
To reduce radiation damage, crystals were transferred in a cryo-solution and flash 
cooled in liquid nitrogen according to Hope (1988). Since Rap1GAP crystals were 
rather sensitive to osmotic changes, crystals were transferred in several steps in the 
cryo-solution thereby slowly increasing the cryo-protectant.    
Initial tiny needles appearing after 14 days were obtained using Crystal Screen II 
from Hampton (Hampton Research, Laguna Hills, USA). The needles could be 
optimised in size using streak seeding and the following condition: T = 4 °C, 
[Rap1GAP] = 60 mg/ml, 550 mM ammonium sulfate, 30 mM citrate (pH 5,6), 240 mM 
potassium sodium tartrate. However, these needles did not diffract X-rays at all. 
A second condition resulting in spherulites was found at 12 °C using the PEG-Ion 
screen from Hampton and a C-terminally truncated Rap1GAP construct (75-405). 
This condition could be improved to obtain tiny needles: [Rap1GAP] = 40 mg/ml, 
8% PEG 2000 MME, 100 mM lithium acetate, T = 12 °C. Using the same condition 
but switching back to the Rap1GAP75-415 construct resulted in small 3-dimensional 
crystals. Crystal size could be improved by using the previously described fully active 
Rap1GAP75-415,Q204A mutant which also showed a 3-fold higher amount of soluble 
protein than wild-type. The optimal crystallisation condition resulting in crystals with 
dimensions 400 x 100 x 50 µm3 after 4 days were: [Rap1GAPQ204A] = 45 mg/ml, 
9% PEG2000 MME, 230 mM lithium acetate, 7% MPD with at least 4 µl drops, 
T = 12 °C. The best cryo-condition found for this crystal form was 
8% PEG 2000 MME, 20% MPD, 20 mM HEPES (pH 7,5), 5 mM DTE in which the 
crystals had to be slowly transferred in three steps over 30 min.   
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Since these crystals displayed a rather poor diffraction quality, bad reproducibility and 
a very large unit cell, it was decided to search for a new crystal form. Using similar 
conditions but re-screening 50 different salts, a new crystal form was discovered. 
Crystals with the final size of 300x100x50 µm3 appearing after 7 days were finally 
obtained with the following reservoir conditions: [Rap1GAP] = 20 mg/ml, 
9% PEG 2000 MME, 100-200 mM MgSO4, 5-7% MPD, 100 mM Hepes (pH 7,1). The 
optimal cryo-condition found for these crystals was 20% PEG 2000 MME, 100 mM 
MgSO4, 5% MPD, 100 mM Hepes (pH 7,1).   
Mercury substituted crystals could be obtained by incubating crystals for 30 min in 
cryo-solution containing 1 mM HgCl2. Incorporation of mercury was confirmed by 
dissolving crystals in sinapinic acid matrix and by MALDI analysis as described in 
3.3.4. 
 
3.4.2 Data collection and processing 
All frozen crystals were first tested at 100 K on a copper rotating X-ray anode with an 
osmic mirror (λ = 1,5419 Å, 50 kV, 100 mA, 0,1 mm collimator). The final datasets 
were obtained at beamline ID14-EH1 at the European synchrotron radiation facility 
(ESRF, Grenoble, France) at a wavelength of 0,934 Å. An ADSC Q105 CCD-detector 
was used. For the native and the selenomethionine substituted crystal, the detector 
distance was 270 mm and the oscillation range 0,6°. 207 frames were collected for 
the native crystal and 423 frames for the selenomethionine substituted crystal. The 
quality of the dataset was validated by calculating Rsymm which compares symmetry 
related reflections according to Equation 1. 
 ∑∑
∑∑ −
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symm I
II
R  Equation 1 
h, k, l - indices of independent reflections with the average intensity <I>  
Ii - intensities of independent reflections.  
 
Data were processed using XDS/XSCALE package (Kabsch, 1993). 
Based on the volume of the asymmetric unit and the molecular weight of the protein, 
the number of molecules in the asymmetric unit can be estimated (Matthews, 1968). 
The Matthew coefficient VM is derived by Equation 2. 
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 ZWM
VVM ⋅⋅=  Equation 2 
MW: Molecular weight of the monomer in Dalton 
V:  Volume of the asymmetric unit in Å3 
Z:  Number of molecules in the asymmetric unit 
 
The average Matthew coefficient of a protein crystal is 2,5 Å3/Da corresponding to a 
solvent content of 50% (Matthews, 1968). The solvent content xS of a crystal can be 
estimated by Equation 3. 
 
M
3
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NV
11x             −⋅⋅−= ρ  Equation 3 
Vm =  Matthew coefficient 
NA =  Avogadro constant 
ρP =  protein density  ~ 1.35 g/cm3 
  
3.4.3 Phase determination 
A structure factor Fhkl can be represented as complex vector according to Equation 4 
(Drenth, 1999; Rhodes, 2000). 
 hklhklhkl iBAF +=  Equation 4 
where Ahkl is a vector of length ΙAhklΙ on the real-number line, and Bhkl is a vector of 
length ΙBhklΙ on the imaginary-number line. Fhkl can be decomposed into its amplitude 
ΙFhklΙ and its phase angle αhkl which is the angle, the vector makes with the real 
number line (Equation 5).  
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απααα ⋅=⋅=+⋅=  Equation 5 
in which α is the phase angle in radians and α’ the angle in cycles. 
The electron density ρ at any point x, y, z can be calculated by Fourier synthesis 
according to equation 6 if the structure factors Fhkl of a crystal (Equation 5) are 
determined . 
 
 
 
Materials and Methods 
43 
 ∑∑∑ −++−⋅=
h k l
hkl
hkl
)'lzkyhx(i2eF
V
1)z,y,x( απρ  Equation 6 
in which V is the volume of the unit cell and h,k,l are the indices of independent 
reflections. 
The amplitude │Fhkl│ of every structure factor is proportional to the square root of the 
measured intensity, (Ihkl)½. The phase angle α’ of every structure factor can 
principally be determined by four different techniques: Isomorphous replacement, 
single or multiple wavelength anomalous diffraction, molecular replacement or direct 
methods. In this work, isomorphous replacement and single wavelength anomalous 
diffraction have been used. 
The isomorphous replacement method requires the attachment of heavy atoms to the 
protein molecules in the crystal. The heavy atom must not disturb crystal packing or 
the conformation of the protein. Furthermore, there must be measurable changes in 
at least a moderate number of reflection intensities between a native and derivative 
dataset. These intensity differences are then exclusively due to the attached heavy 
atoms. 
By analysis of a difference Patterson function, the heavy atoms can be located in the 
asymmetric unit (Drenth, 1999; Rhodes, 2000). When these sites of the heavy atoms 
are known, one can calculate the structure factors of the heavy atoms alone 
according to Equation 7. 
 ∑= ++⋅⋅=
n
j
lzkyhxi
jhkl
jjjef
1
)(2F π
 Equation 7 
where n is the number of heavy atoms located by the difference Patterson function. 
A single structure factor of the derivative dataset FHP can be expressed by the 
corresponding structure factor of the native dataset FP and the structure factor FH 
derived from the heavy atoms according to Equation 8. 
 PHHP FFF +=  Equation 8 
│FP│ and │FHP│ can be derived from the measured intensity of the reflection. The 
structure factor FH including phase angle can be calculated according to Equation 7. 
The phase angle of structure factor FP can then be determined geometrically or 
numerically (Rhodes, 2000). 
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An alternative means of obtaining phases from heavy-atom derivatives takes 
advantage of the heavy atom’s capacity to absorb X-rays of specified wavelength. 
The pairs of structure factors Fhkl and F-h-k-l are called Friedel pairs, and it can be 
shown that │Fhkl│=│F –h-k-l│ and αhkl = -α-h-k-l (Friedel’s law, Friedel, 1913). However, 
as a result of X-ray absorption by heavy atoms, Friedel pairs are not equal in intensity 
and do not have the same absolute value of α. This phenomenon is called 
anomalous scattering or anomalous dispersion.  
FHPλ1 represents a structure factor for the heavy atom derivative which is measured 
at a wavelength λ1 where anomalous scattering does not occur. It can be expressed 
by FHPλ2 which represents the equivalent structure factor at a wavelength λ2 where 
anomalous scattering does occur according to Equation 9. 
 ir
HP
hkl
HP
hkl FFFF
12 ∆+∆+= λλ  Equation 9 
where the vectors representing anomalous scattering contributions are ∆Fr (real) and 
∆Fi (imaginary).  
The magnitude of anomalous scattering contributions ∆Fr and ∆Fi for a given element 
at a given wavelength is constant and can be found in crystallographic tables. The 
phases of ∆Fr and ∆Fi can be computed when the locations of the anomalous 
scatterers are determined by Patterson methods (Drenth, 1999). The phase angle of 
structure factor FHP can then be determined from the difference in Fhkl and F-h-k-l by 
geometrical or numerical means (Rhodes, 2000). 
 
SHELXD (Schneider and Sheldrick, 2002) was used to find selenium sites of 
selenomethionine substituted crystals by using the anomalous signal of the selenium 
atoms and the isomorphous signal between native and selenomethionine substituted 
crystals (SIRAS phasing). Selenium sites were refined and initial phases calculated 
using the program Sharp (Buster Development Group). Solvent flattening was carried 
out using the program SOLOMON. An initial model was built using the program XFit 
from the XtalView program package (McRee, 1999). 
 
3.4.4 Refinement 
Refinement is an iterative process required to improve the initial phases and to 
correct the geometry of the model. An initial model is improved by minimizing the 
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energy of a geometrical and a crystallographic energy term. The geometrical term of 
a model contains bond length, bond angles, torsion angles, non-bonded interactions, 
hydrogen bonds, van-der-Waals interaction, planar restraints and chiral centre 
restraints of the input model. The crystallographic term appreciates the amplitudes of 
the measured reflections ׀Fobs ׀. With the refined model, new structure factors (Fcalc) 
are calculated. A measure of the quality of a model can be derived from Rcryst which 
compares measured and calculated structure factors according to Equation 10. 
 ∑
∑ −=
obs
calcobs
cryst F
FF
R  Equation 10 
Using the calculated phases and the measured reflection intensities, an improved 
electron density map can be calculated. Since the calculated phases are biased 
towards the potentially wrong model, a test set of reflections is excluded from the 
refinement (typically 5–10% of the reflections). These reflections are used to 
calculate Rfree similar to Equation 10 (Brunger, 1992; Brunger, 1997). Rfree is a rather 
non-biased measure of the quality of the protein model.  
The program Refmac5 was used for refinement here (Murshudov et al., 1997). 
Typically, it refines the temperature factors of every atom and then the position.  
5% of the reflections were used as test set. A typical refinement cycle started with 
10 cycles of TLS (translation, libration, screw-rotation displacement) refinement using 
10 independent protein bodies (Winn et al., 2003) followed by 5 cycles of positional 
refinement using a high weight for the geometrical energy term in comparison to the 
crystallographic term.  
The model was validated by the programs Procheck (Laskowski et al., 1993) and 
Whatcheck (Hooft et al., 1996). Contacting amino acids in the Rap1GAP dimer 
interface were identified using the CCP4 program Contact (Bailey, 1994). The plot of 
contacting amino acids in the dimer interface was generated using the program 
Ligplot (Wallace et al., 1995). The area of buried surface between two monomers 
was determined using the CNS program suite (Brunger et al., 1998). The structure 
alignment between the catalytic domain of Rap1GAP and Ras was performed using 
the program structalign (Shindyalov and Bourne, 1998). 
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3.4.5 Figure preparation 
Ribbon plots and ball-and-stick models were prepared using the program Molscript 
(Kraulis, 1991). All surface plots were prepared using the program GRASP (Nicholls 
et al., 1993). Electron density plots were prepared using the program Bobscript 
(Kraulis, 1991). The stereo image was generated using the program gl_render and 
rendered with Povray (www.povray.org). All other plots were rendered with Raser3D 
(Merritt and Bacon, 1997). The final figures were prepared with Adobe Photoshop 
and CorelDraw10 (Corel Corporation). 
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4 Results 
4.1 Initial characterisation of Rap1GAP 
4.1.1 Expression 
It has previously been shown by deletion analysis that residues 75–415 of Rap1GAP 
are sufficient for full Rap1GAP activity (Rubinfeld et al., 1991). To characterise 
Rap1GAP mediated catalysis, the catalytic domain of Rap1GAP (amino acids  
75–415, from here Rap1GAP) was expressed as GST fusion and purified by affinity 
chromatography according to Brinkmann (2000) (see 3.3.5). To remove bacterial 
GroEL, which was bound to Rap1GAP, the column had to be washed extensively 
with buffer containing potassium ions and ATP. GST was finally cleaved with 
thrombin to obtain catalytically active Rap1GAP. A typical protein purification yielding 
at least 80% pure protein is documented in Figure 16.  
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Figure 16. Human Rap1GAP was expressed in bacteria as GST fusion and purified using 
affinity chromatography.    1) Marker.    2) Non-induced culture.     3) Induced culture.  
4,5)  Soluble extract before (4) and after (5) application on a GSH column.  
6) Purified protein after thrombin cleavage.  
 
4.1.2 Biochemical characterisation of Rap1GAP 
The enzymatic activity of Rap1GAP was characterised in cooperation with 
T. Brinkmann (Brinkmann et al., 2002). To obtain Michaelis-Menten parameters for 
the Rap1GAP stimulated GTPase reaction, Rap1GAP was used in constant 
concentration (100 nM) as enzyme and Rap1•GTP in varying concentrations as 
substrate. Initial rates of GAP stimulated GTP hydrolysis were determined by a 
radioactive charcoal assay (3.3.15). The reaction showed a typical Michaelis-Menten 
behaviour (Figure 17).   
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Figure 17. Michaelis-Menten kinetic of the Rap1GAP-stimulated reaction. 100 nM Rap1GAP 
or GST-Rap1GAP were used as enzyme and increasing concentrations of 
Rap1•[γ-32P]GTP as substrate, in standard buffer at 25 °C . GTP hydrolysis was 
monitored by measuring Pi release. Observed rate constants were fitted to 
Michaelis-Menten equation for determination of kcat and Km. These data were 
provided by T. Brinkmann (Brinkmann et al., 2002).   
By non-linear regression fitting of the observed rates, a kcat of 6 sec-1 and a Km of 
50 µM were obtained. The kcat is in a similar range to that of GAP stimulated 
reactions of Ras (Ahmadian et al., 1997a), Rho (Graham et al., 1999), Ran (Klebe et 
al., 1995) and Rab (Albert et al., 1999) which are all in the range of 5 to 20 sec-1. 
When comparing the kcat (6 sec-1) to the non-stimulated reaction (2·10-5 sec-1) under 
these conditions, a more than 105-fold acceleration of GTP hydrolysis in Rap1 is 
observed. These results clearly indicate that the purification protocol yields a highly 
active, folded Rap1GAP protein. 
GST often stabilises proteins which are expressed as GST fusions. Since the 
following experiments required many Rap1GAP mutants and it was speculated that 
the mutants might be less stable than wild-type, GST-Rap1GAP was also tested for 
activity using Michaelis-Menten kinetics (Figure 17). Indeed, similar rates for  
kcat (6 sec-1) and an only somewhat higher Km (160 µM) were observed. Thus, the 
GST fusion proteins could be used for the subsequent experiments.  
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4.1.3 Arginine mutants 
With the exception of RanGAP and possibly ArfGAP, GAPs for small GNBPs contain 
a catalytic arginine which is inserted into the catalytic site of the GNBP to 
complement the incomplete catalytic machinery. It was asked whether Rap1GAP 
also employs a catalytic arginine which should then be conserved among different 
Rap1GAPs.  
To identify the conserved arginines in Rap1GAP, sequences from human Rap1GAP, 
Spa1, E6TP1, Drosophila melanogaster Rap1GAP and Caenorhabditis elegans 
Rap1GAP and Spa1 were aligned (Table 3).  
Seven conserved arginines were identified (R91, R128, R132, R284, R286, R388 
and R390). To test whether they are involved in catalysis, they were individually 
mutated to alanine and the mutant proteins were purified according to standard 
procedures. For one of the mutants, R132A, only little amount of soluble protein 
could be obtained which was only partially cleavable by thrombin indicating that the 
mutation destabilised the protein. The activity of the mutants was checked at a 
Rap1•GTP concentration of 200 µM using the charcoal assay (Figure 18). 
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Figure 18. Probing the GAP mechanism by arginine mutations. Invariant arginine residues 
were mutated to alanine. The mutants were purified and the GAP activity was 
measured under the standard condition, which is 100 nM Rap1GAP, 
200 µM Rap1•[γ-32P]GTP in standard buffer at 25 °C. Initial rates were determined by 
measuring several time points and plotted in a bar diagram. Mutants indicated with * 
were examined by T. Brinkmann (Brinkmann, 2000).   
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Under these conditions, the R91A, R128A, R286A, and R390A mutants retained 
more than 50% of wild-type activity whereas the mutants R284A and R388A 
exhibited a 3- to 4-fold decrease in GAP activity. The mutant R132A showed between 
10% and 20% of the wild-type activity depending on the preparation, which might be 
explained by the instability of this protein. None of the mutants had a dramatically 
decreased Rap1GAP activity as expected for a catalytic arginine which in the case of 
RasGAP reduces activity more than 1000-fold when mutated to alanine. It can be 
concluded that Rap1GAP does not possess a catalytic arginine indicating a novel 
mechanism of GAP mediated GTP hydrolysis. 
   
4.1.4 Lysine and glutamine mutants 
Since none of the arginines appeared to contribute to catalysis, other conserved 
residues were analysed which might replace the missing arginine residue. Since 
lysine, similar to arginine, could in principle be used for stabilisation of the GTP 
hydrolysis transition state as found for the nitrogenase complex in the ADP•AlF −4  
bound state (Schindelin et al., 1997), all three invariant lysine residues of Rap1GAP 
were mutated to alanine and the activity of the mutants measured using the charcoal 
assay. While lysine K368 does not appear to be important for catalysis, a large drop 
in catalytic activity was found for the mutants K194A and K285A. Using a GAP 
concentration of 2 µM and 5 µM, respectively, it was estimated that K194A and 
K285A are at least 25- and 100-fold less active than the wild-type at a concentration 
of 200 µM Rap1•GTP (Figure 19A). 
To find out whether the mutants K194A and K285A have a lower affinity to Rap1 or a 
reduced catalytic activity, they were analysed using Michaelis-Menten kinetics 
(Figure 19B). It was not possible to saturate these mutants by using up to 800 µM 
Rap1•GTP. This clearly shows that the mutants have a reduced affinity for 
Rap1•GTP. However, it can not be excluded that they might also have reduced 
catalytic activity. 
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Figure 19. Mutational analysis of conserved lysine and glutamine residues.   A) Conserved 
lysines and glutamines of Rap1GAP were mutated to alanine and the GAP activity 
analysed under standard conditions. Mutants indicated with * were analysed by T. 
Brinkmann. For the mutants K194A and K285A, an enzyme concentration of 2 µM 
and 5 µM was used.    B) For further analysis, Michaelis-Menten kinetics of mutants 
K194A and K285A (*) were measured under standard conditions, shown in 
comparison to wild-type. The inset has a different scale. 
Members of the Rap family do not use a catalytic glutamine, nevertheless are able to 
hydrolyse GTP. Since glutamine is of crucial importance for the GTP-hydrolysis 
reaction of most other small GNBPs, it was examined whether Rap1GAP might 
provide a catalytic glutamine in trans to stimulate GTP hydrolysis in Rap1. All four 
invariant glutamine residues (glutamines Q204, Q280, Q281 and Q298) were 
mutated to alanine and the activity of the mutants was analysed. As shown in  
Figure 19A, the Q204A mutation had no effect on catalysis. The Q280A and Q281A 
mutants had a 2-fold and the Q298A mutant a 6-fold reduced activity at a 
concentration of 200 µM Rap1•GTP. This is, however, much less than what would be 
expected for a residue replacing glutamine Q61 whose mutation in Ras or Ran 
reduces GAP activity by more than five orders of magnitude. 
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hsRap1GAP 75 :
hsSpa1 205 :
hsE6TP1 476 :
dmRapGAP 215 :
ceRapGAP 21 :
ceSpa1 172 :
hsTuberin - :
PTTKVKLE-CNPTARIY KHFLGKEHFNYYSLDTALGHLVFSLKYDVIGD QEH------ LRLLLRT------KCRTYHDVIPISCLTEFPNVVQMAKLVC
RTSAYSLEHADLGAGYY KYFYGKEHQNFFGMDESLGPVAVSLRREEKEG-SGGGTLHSYRVIVRTTQLRTLRGTISEDALPPGPPRGLSPRKLLEHVAP
VKRYIVEHV-DLGAYYY KFFYQKEHWNYFGADENLGPVAVSIRREKPDEMKENGSPYNYRIIFRTSELMTLRGSVLEDAIPSTAKHSTARGLPLKEVLE
TTWMAKFE-TDDTAKCY RFYAAREHSNLIGLDEQLGPILLSIKTENVAN QEH------ MRILMRL------RTGTMHELLPVSCLLPQPSPAKMAHTLN
SCARFKLE-TDETSHCY RHFFGREHHDFFANDPIVGPLVLSVRTEVISS CDH------ FRIILRT------RKGTIHEIVSATALADRPSASRMAKLLC
RQPKTVIEPQDIGSYYY HCFISKNHIEYLGMDDILGPISISMVREIVDR-KES YSI-- YRMIVRISDQKTIRVAVPEEALSTPEGSDRATRPLMRELLE
----------------------------------------------------------------------------------------------------
hsRap1GAP 162 :
hsSpa1 304 :
hsE6TP1 575 :
dmRapGAP 302 :
ceRapGAP 108 :
ceSpa1 269 :
hsTuberin 1 :
EDVNVDRFYPVLY P ASRLIVTF EHVISN
----
NFKFGVIYQKLGQT-SEEELFSTNEESPAFVEFLEFLGQKVKLQDFKG---FRGGLDVTHGQTGTE
QLSPSCLRLGSAS P VPRTLLTL EQV SF
----
QRKVGILYCRAGQG-SEEEMYNNQEAGPAFMQFLTLLGDVVRLKGFES---YRAQLDTKTDSTGTH
HVVPELNVQCLRLAFNT VTEQLMKL QG NYQQKVGIMYCKAGQS-TEEEMYNNESAGPAFEEFLQLLGERVRLKGFEK---YRAQLDTKTDSTGTH
ENITVDHFMPILC P ASQ SVY EHV VS
----
HFKFGVLYQRYGQT-TEEELFGNQQTSPAFDEFLDVLGQRIRLKDHKG---YRGGLDIQNGHTGDT
EEITTEQFSPVAF PGGSE VQY EHV TN
----
TYKFGVIYQKGGQT-TEEQLFGNPHGSPAFDEFLSMIGDSVQLNGFQK---YRGGLDTAHNQTGHQ
IVCPKISFGILRPSIQS RVEE MKI QPIYTRYKVGIMLCKNEQS-TEEQMYNNEFSTPSFDEFLDFLGQRVTLKGFEA---YKGGLDTRGDTTGTH
-------- QSFERSVQLL QIPSYDTHKIAVLYVGEGQSNSELAILSNEHGSYRYTEFLTGLGRLIELKDCQPDKVYLGGLDV-CGEDGQF
hsRap1GAP 254 :
hsSpa1 396 :
hsE6TP1 671 :
dmRapGAP 394 :
ceRapGAP 200 :
ceSpa1 365 :
hsTuberin 1 :
SVYCNFRN-KEIMFHVSTKLPYTEGDAQQLQRKRHIGNDIVAVVFQDENT-PFVPDMIASNFLHAYVVVQAEGGGPDGPLYKVSVTARDDVPFFGPPLPD
SLYTTYQD-HEIMFHVSTMLPYTPNNQQQLLRKRHIGNDIVTIVFQEPGSKPFCPTTIRSHFQHVFLVVRAHTPCRPHTTYRVAVSRTQDTPAFGPALPA
SLYTTYKD-YEIMFHVSTMLPYTPNNKQQLLRKRHIGNDIVTIVFQEPGAQPFSPKNIRSHFQHVFVIVRVHNPCSDSVCYSVAVTRSRDVPSFGPPIPK
AVYEVFKE-REIMFHVSTLLPHTEGDPQQLQRKRHIGNDIVAIVFQETNT-PFSPDMIASHFLHAFIVVQPIEPNTPHTRYKVSVTARDDVPFFGPTLPN
SVFSEFKN-REIMFHVSTMLPYTIGDAQQLQRKRHIGNDIVAIIFQEANT-PFAPDMIASNFLHAYVVVQPIDALTDRVRYRVSVAARDDVPFFGPTLPT
SIYSEYQA-HEIMFHVSTLLPFTPSNRQQLSRKRHIGNDMVTIVFQEPGALPFSPITVRSHFQHVFIIVRVHNECSENVTYSVAVSRSKDVPAFGPPVPK
T-YCWHDDIMQAVFHIATLMPTKDVDKHRCDKKRHLGNDFVSIVYNDSGED-FKLGTIKGQFNFVHVIVTPLDYECNLVSLQCRKDMEGLVDTSVAKIVS
hsRap1GAP 352 :
hsSpa1 495 :
hsE6TP1 770 :
dmRapGAP 492 :
ceRapGAP 298 :
ceSpa1 464 :
hsTuberin 1 :
PAV--FRKGPEFQEFLLTKLINAEYACYKAEKFAKLEERTRAALLETLYEELHIHSQSMMGLGGDE
GGGP-FAANADFRAFLLAKALNGEQAAGHARQFHAMATRTRQQYLQDLATNEVTTTSLDSASSRFG
-GVT-FPKSNVFRDFLLAKVINAENAAHKSEKFRAMATRTRQEYLKDLAEKNVTNTPIDPSGKFPF
PAV--FRKGQEFKEFILTKLINAENACYKAEKFAKLEQRTRTSLLQNLCEELREKTRDFLGTDLSQ
PSI--FKRGQDFRNFLLTKLINAENAAYKSSKFAKLAERTRSSLLDGLHATLRERAEFYATPLLES
GAC--FSKCAEFHDWLLTKIINAENAVHRSKKFATMAARTRREALRDLVENYVGPHQNEGASKIAS
DRNLPFVARQMALHANMASQVHHSRSNPTDIYPSKWIARLRHIKRLRQRICEEAAYSNPSLPLVHP
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Table 3  Sequence alignment of various Rap1GAPs and Tuberin. The sequences are Homo sapiens Rap1GAP (Swiss-Prot accession number (SW) P47736),  
Homo sapiens Spa1 (SW O60618), Homo sapiens E6TP1 (SW Q9UNU4), Drosophila melanogaster RapGAP (SW O44090), Caenorhabditis elegans  
RapGAP (SW P91315), Caenorhabditis elegans Spa1 (SW Q20016) and Homo sapiens Tuberin (SW P49815). Completely conserved residues are boxed in 
red, highly conserved residues (>50 %) in green. Secondary structure elements as derived from the Rap1GAP structure are depicted on top (Figure 24A) . 
The interaction helix with the catalytic asparagine is coloured in purple. Mutations in Tuberin found in tuberous sclerosis patients are indicated with S. 
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4.2 The Rap1GAP structure 
From the results in chapter 4.1 it was concluded that Rap1GAP uses a completely 
novel mechanism to stimulate GTP hydrolysis in Rap1. No arginine is provided for 
catalysis and no catalytic glutamine is involved in this reaction. However, two lysine 
residues, lysine K194 and lysine K285, were identified whose mutation drastically 
reduced the Rap1GAP activity. To clarify the role of these two lysines and to get 
insights into the mechanism of GTPase stimulation, the structure of Rap1GAP was 
determined by X-ray crystallography. 
 
4.2.1 Purification 
Since the initially described purification procedure yielded protein which still 
contained GroEL contaminations, Rap1GAP was further purified using size exclusion 
chromatography. HEPES was chosen as a buffer, since PBS in which the protein 
was initially purified is not suited for crystallisation and since it was observed that 
diluting the protein in TRIS buffer led to protein precipitation. In HEPES buffer, the 
protein could be concentrated up to 100 mg/ml without any precipitation. Surprisingly, 
Rap1GAP did not elute as a monomer but as a protein with an apparent mass of 
100 kD from gel filtration. 
 
4.2.2 Degradation and partial digest 
Rap1GAP was more than 95% pure after size exclusion chromatography as judged 
by SDS-PAGE analysis (Figure 20). However, after several days at 8 °C, Rap1GAP 
degradation was observed (Figure 20, lane 2 and 4). This implies that Rap1GAP has 
flexible loops which are accessible for contaminating proteases. Degradation poses a 
problem for crystallisation for which stable fragments are required. 
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Figure 20. Degradation of Rap1GAP.   1) Marker   2) Rap1GAP after 8 days at 8 °C.   3) Rap1GAP 
after purification. 4) Rap1GAP after 14 days at 8 °C.  
Results  
54 
 
Figure 21. Partial digests of Rap1GAP (3.3.10) with trypsin (A), elastase (B) and papain (C). 
Digests were started by addition of protease. After the indicated time points, 
aliquots were taken and analysed by SDS-PAGE using 15% polyacrylamide gels. 
To obtain a stable Rap1GAP fragment, various proteases were tested in a partial-
digest experiment (see 3.3.10). Trypsin, elastase and papain led to specific 
degradation bands (Figure 21). 
A peptide fragment which appeared in degradation experiments and partial digests 
run as a 24 kD band in SDS-PAGE. Its exact mass was determined by MALDI to be 
24,4 kD. By further MALDI analysis, it was shown to be a C-terminal Rap1GAP 
fragment (see 3.3.9) corresponding to amino acids 178-415 of Rap1GAP. This 
fragment was expressed as a GST fusion in E.coli but appeared only in the insoluble 
fraction.   
 
4.2.3 High throughput cloning  
To obtain a soluble stable Rap1GAP fragment for crystallisation, various Rap1GAP 
homologues were tested for expression. Since human Rap1GAP could be expressed 
as a soluble GST fusion in bacteria and Rap1GAPs show an extensive homology it 
was reasoned that this expression system is also appropriate for the other Rap1GAP 
homologues.  
Based on the Rap1GAP construct, two constructs of human E6TP1, two of human 
Spa1, seven of Drosophila melanogaster Rap1GAP, one of Dictyostelium Rap1GAP 
and five of human Tuberin were prepared (see 3.2.11). However, the expressed 
proteins were either insoluble, degraded or precipitated upon removal of GST. None 
of them could be used for crystallisation trials. 
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Consequently, shortened human Rap1GAP constructs were prepared since flexible 
N- or C-termini might interfere with crystallisation. An N-terminal truncated 
GST-Rap1GAP construct comprising amino acids 85-405 could be prepared and 
showed Rap1GAP activity. However, it was not possible to remove the GST by 
thrombin cleavage. Probably, the thrombin cleavage site was not accessible. 
However, Rap1GAP75-405 truncated by ten amino acids at the C-terminus could be 
purified in large amounts and showed Rap1GAP activity comparable to the original 
construct (data not shown). 
 
4.2.4 Crystallisation 
Rap1GAP and Rap1GAP75-405 were used for crystallisation trials using the hanging 
drop method. As an initial condition, the standard solutions from Hampton Research 
screens were used in a 1:3 dilution. To reduce degradation problems, all 
crystallisation trials were carried out at 4 °C or 12 °C.  
Initial tiny protein needles from Rap1GAP could be obtained using ammonium sulfate 
as a precipitant at 4 °C (Table 4A, details in 3.4.1). The size of the crystals could be 
improved by adjusting these conditions (Table 4B). However, this crystal form did not 
diffract X-rays.  
For Rap1GAP75-405, spherulites (microcrystals) were found using PEG as a 
precipitant (Table 4C). Optimisation of the condition led to tiny needles (Table 4D). 
Using the same condition but switching back to Rap1GAP, small needles were 
obtained (Table 4E) which could be optimised to yield small three-dimensional 
crystals (Table 4F). The size of these crystals could be increased by using the 
Rap1GAPQ204A mutant (Table 4G). This mutant has similar activity as the wild-type 
(4.1.4) but could be purified in 3-fold higher amounts. The optimised conditions 
yielded protein crystals with dimension 200x100x100 µm3 (Table 4H). 
These crystals were tested for diffraction. However, even after extensive adjustment 
of the cryo freezing conditions, their maximal diffraction was only 3,5 Å at a 
synchrotron beamline. Furthermore, the crystals exhibited a large orthorhombic unit 
cell size (300 x 140 x 100 Å3) with predicted 8-12 monomers in the asymmetric unit 
which made de novo phase determination difficult to achieve.   
To find another crystal form with smaller unit cell, new crystal screens were 
performed. By modifying the pH and testing 50 new salt conditions, a new  crystal 
form with smaller unit cell size was discovered (Table 5). These crystals could be
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Table 4  Photos of several Rap1GAP crystals.   A) Initial needles of Rap1GAP using ammonium sulfate as a precipitant.   B) Fine-tuned condition of A.    
C) Rap1GAP75-405 spherulites using PEG as a precipitant.   D) Fine-tuned condition of C.   E) Reservoir solution similar than in D but Rap1GAP used instead 
of Rap1GAP75-405.     F) Condition similar to E but Rap1GAPQ204A used instead of Rap1GAP.       G,H) Optimised condition from F.     
I, J, K,L) Final Rap1GAPQ204A crystals. The bar indicates 100 µm.  
Results  
57 
improved to a final size of 300x100x100 µm3 (Table 4 I, J, K). They were flash cooled 
in a cryo-solution and diffracted to 3,2 Å on a copper rotating anode. 
Selenomethionine substituted protein was prepared and crystallised by using the 
same conditions as for the wild-type protein.  
 
4.2.5 Structure determination 
Datasets of native and selenomethionine substituted Rap1GAP crystals were 
collected at the European Synchrotron Radiation Facility (ESRF), beamline ID14-EH1 
in Grenoble. The native crystals diffracted to a maximal resolution of 2,9 Å and have 
an orthorhombic space group with unit cell dimensions 170x224x49 Å3. Assuming 
four molecules in the asymmetric unit, a Matthew coefficient of 3,1 Å3/Da was 
calculated, indicating approximately 60% solvent content in the crystal. The 
selenomethionine substituted crystals diffracted to 3,1 Å and have nearly identical 
unit cell dimensions. Data collection statistics of both native and selenomethionine 
substituted crystals are summarised in Table 5. 
 
Table 5  Data statistics of native and selenomethionine substituted crystals. 
Data collection Native SeMeta 
Wavelength 0,934 Å (ID14-EH1) 0,934 Å (ID14-EH1)  
Resolution 20 – 2,9 Å 20 – 3,1 Å 
Space group P2121 2 P2121 2 
Unit cell a = 170,7 Å, b= 224,4 Å, 
c = 48,7 Å, α = β = γ = 90 °
a = 171,3 Å, b= 224,2 Å, 
c = 48,8 Å, α = β = γ = 90 ° 
VM (Å3/Da) 3,09 3,10 
Completeness (%) 98,2  97,9  
Reflections (unique) 208333 (42290) 356220 (65145) 
Rsymma,b 4,9 (4,8) 5,5 (5,4) 
I/σ(I) 17,3 (4,0) 13,3 (4,0) 
Wilson-B (Å2) 71 73 
aFor the SeMet data Friedel pairs were treated as separate observations 
bRsym = Σ | I(h)j - <I(h)> | / Σ I(h)j where I(h)j is the scaled observed intensity of the i-th symmetry-
related observation of reflection h and <I(h)i> is the mean value 
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Using the anomalous differences of the derivative data and the isomorphous 
differences between the native and selenomethionine data, initial protein phases 
could be calculated and improved by solvent flattening. The electron density 
indicated four molecules in the asymmetric unit, although only three were clearly 
defined in the electron density. The best defined molecule (in the following 
molecule A) was built. By using the non-crystallographic symmetry operators derived 
from the selenium sites, the model could be extended to the asymmetric unit. After 
few rounds of initial rigid body refinement, the model was improved by several rounds 
of B-factor and positional refinement and manually rebuilt. Apart from the protein 
molecules, 60 water, 2 sulfate ions and 2 MPD molecules were included in the final 
model. The model has an Rcryst of 23,3% and an Rfree of 27,6% which is in the normal 
range of models at this resolution. The Ramachandran plot shows no residues in the 
disallowed region (Figure 22). This proves that the weighting of the geometry term 
during refinement was high enough. Phasing and refinement statistics are 
summarised in Table 6.  
 
Table 6 Phasing and refinement statistics of the Rap1GAP model.   
 
 
 
 
Phasing statistics  
Phasing power anomalous (highest resolution shell) 1,3 (0,8) 
Phasing power isomorphous (highest resolution shell) 2,0 (2,1) 
FOM (highest resolution shell)  46% (34%) 
FOM after solvent flattening (highest resolution shell)  83% (64%) 
  
Refinement statistics   
Resolution (Å) 15-2,9 
Unique reflections (test set) 40001 (2103) 
Number of amino acids (protein atoms) 1041 (8168) 
Number of sulfate ions 2 
Number of MPD molecules 2 
H2O 60 
Rcryst (Rfree) (%) 23,3 (27,6) 
Resolution (Å) 15-2,9 
  
Rms deviation from standard geometry  
Bond length (Å) 0,015 
Angle (°) 1,7 
Torsion angle (°) 7,6 
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Figure 22. Ramachandran plot showing the torsion angles of all peptide bonds of the Rap1GAP 
model. Triangles represent glycine and proline residues, squares all other amino 
acids. 85% of all amino acids have torsion angles in the most favoured region (red 
background), 14,5% in the additional allowed region (yellow background) and  
0,5% in the generously allowed region (red squares). None of the residues has a 
phi-psi combination in the disallowed region. The plot was generated using the 
program Procheck (Laskowski et al., 1993).    
Two of the four molecules are well defined in the electron density (molecule A and 
molecule C), molecule B is less well defined and molecule D could be build only 
partially. Additionally, molecule D has the highest temperature factors (B-factors) and 
molecule B has higher temperature factors than molecule A and C (Figure 23). This 
indicates that molecule B and especially molecule D are not well ordered within the 
crystal. This assumption can be explained by the crystal packing since molecules B 
and D have only few crystallographic contacts. Especially molecule D has only 
contacts to symmetry-related D molecules. In contrast, molecule A interacts 
extensively with molecule C leading to stabilisation in the crystal. Since disordered 
atoms in a crystal do not contribute significantly to the diffraction pattern, this would 
explain why the R values from refinement are in a normal range despite more than 
200 amino acids of molecule D are not included in the model. A disordered 
molecule D could also be the reason for the rather poor diffraction quality of the 
crystals.  
The model of molecule A which is described in the following includes amino acids 
78-147, 150-325 and 330-412. Amino acids 146, 147 and 411 are modelled as 
alanines due to missing electron density for the side chains. Molecule B includes 
amino acids 79-145,150-232, 239-242, 250-275, 279-322, 332-411 and several 
residues were modelled as alanines. In molecule C, residues 77-144, 148-323, 
330-409 could be modelled and amino acids 143, 144, 148, 215, 322 were modelled 
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as alanines. Finally, in molecule D, residues 90-103, 113-120, 126-131, 151-154, 
168-186 and 395-409 are built and several residues were modelled as alanines. 
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Figure 23. Temperature (B-) factors of molecules A–D. Molecule A and C have comparable 
temperature factors and nearly all residues could be built. Molecule B has higher 
temperature factors and some residues are missing whereas in chain D, only few 
amino acids could be built which have very high temperature factors indicating the 
high flexibility of molecule D within the crystal lattice. 
 
4.2.6 Topology 
Secondary structure elements were numbered according to their appearance (α1-α9, 
β1-β13, L1-L18), starting from the N-terminus (Table 3, Figure 24, Figure 25). Each 
Rap1GAP molecule consists of two domains, both containing a central β-sheet 
surrounded by α-helices. The smaller domain (residues 75-189) was termed the 
“dimerisation domain”, the larger domain (residues 190-379) which is homologous to 
Tuberin was called the “catalytic domain” (for explanation see below). The long 
C-terminal helix α9 (residues 380-409) folds back from the catalytic onto the 
dimerisation domain. 
The N-terminal dimerisation domain contains a central 5-stranded anti-parallel 
β-sheet (Figure 24, Figure 25). Helix α2 on one side and helices α1, α3 and α9 on 
the other side are packed against the central β-sheet. Helix α9 (amino 
acids 382-412) has extensive hydrophobic contacts to helix α3 and strand β1 of the 
dimerisation domain but nearly no contacts to the catalytic domain.  
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Figure 24. Ribbon type presentation of the Rap1GAP monomer with views from opposing 
sides. In A secondary structure elements are coloured according to the domain 
architecture. In B helices are coloured in red and strands in green. Helix α7 is shown 
in magenta. 
The catalytic domain shows higher sequence conservation than the dimerisation 
domain within the Rap1GAP family. It is built of amino acids 190-379 and contains an 
8-stranded mixed, curved β-sheet. Helices α5 and α8 from one side and helices α4, 
α6 and α7 from the other side are packed against the central β-sheet (Figure 24). 
The catalytic and the dimerisation domain are connected only loosely and it was 
asked whether they might be connected by a flexible hinge. This could be reflected in 
different angles between catalytic and dimerisation domain in the different molecules 
of the asymmetric unit. To test this hypothesis, all visible molecules were overlaid 
and the angles between the domains analysed using the program dyndom (data not 
shown, Bailey (1994)).  
Molecules A, B and C could be overlaid with low deviations of their Cα carbon atoms 
(0,5 Å rmsd for molecule A and B, 0,7 Å rmsd for molecule A and C). No hint for a 
hinge between the both domains was found. Thus in the crystal structure, the two 
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domains appear to be fixed relative to each other, although it cannot be excluded that 
they are more flexible in solution.  
In comparison to GAPs of other GNBPs, the Rap1GAP fold is unique. To find out 
whether other proteins than GAPs possess structural similarity to Rap1GAP, a 
structural homology search was performed against all published protein structures  
using the DALI server (Holm and Sander, 1993). Surprisingly, the closest relative of 
Rap1GAP was found to be the superfamily of small GNBPs including Ras and Rap1 
which have structural homology to the Rap1GAP catalytic domain.  
Strands β1-β5 and additionally helices α1, α2 and α5 can be superimposed to 
strands β6-11 and helices α5, α7, α8 of the Rap1GAP catalytic domain, respectively 
(Figure 25, Figure 26). At the P-loop position of Ras, Rap1GAP has a much longer 
insertion consisting of two loops and helix α4. Switch I of Ras is replaced by an 
insertion in Rap1GAP consisting of an additional strand β7 and a large loop. An 
equivalent to strand β7 in Rap1GAP can be found as strand β2E for example in the 
small GNBPs Ran (Scheffzek et al., 1995) and in the GDP bound forms of Arf 
(Greasley et al., 1995) and Arl (Hillig et al., 2000). Helix α2 of switch II in Ras 
superimposes with helix α7 of Rap1GAP. Finally, helix α3 of Ras is replaced by a 
long loop in Rap1GAP and helix α4 and strand β6 of Ras are completely different 
from strands β12 and β13 in Rap1GAP.  
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Figure 25. Topology of the Rap1GAP monomer (left) shown in comparison to the G domains 
which have an extra β-sheet (β2E) (for example Ran, Arf, Arl right). Helices are 
depicted as red circles, strands as triangles with orientation according to their 
direction in the β-sheet. The secondary structure elements which can be overlaid in 
Rap1GAP and Ras are boxed.  
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Figure 26. Ribbon plot showing the catalytic domain of Rap1GAP (in red) superimposed with 
the aligned Ras molecule in blue (pdb code 121P). Switch II of Ras is coloured in 
cyan, the corresponding helix α7 in Rap1GAP is shown in purple. Clearly, most of 
the secondary structure elements can be superimposed. 
The structural similarity is hardly reflected on the sequence level, for which only 9% 
sequence identity was found. However, the structural similarity clearly suggests that 
Rap1GAP and the family of small GNBPs are derived from a common ancestor. 
 
4.2.7 Description of the dimer  
Rap1GAP (molecular mass of the monomer 39 kD) eluted as an apparent 100 kD 
species in size exclusion chromatography. Two elongated dimers (molecule A-B and 
molecule C-D) with approximate dimensions of 35x35x130 Å3 were observed in the 
asymmetric unit of the crystal (Figure 27A, B). The higher apparent molecular weight 
observed in size exclusion chromatography likely results from the extended shape of 
the dimer leading to a greater hydrodynamic radius than expected for a globular 
protein. The two-fold axis between the two monomers can easily be recognised in 
Figure 27B. 
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Figure 27. Two views of the elongated Rap1GAP dimer. Helix α7 is shown in magenta. The two-
fold axis is indicated in B. 
The size of the dimer interface (Figure 28) was determined to be approximately 
2400 Å2 (see 3.4.5), which is in a typical range for physiological relevant protein 
interfaces (Jones et al., 2000). It is built symmetrically of amino acids from molecule 
A and B (Figure 28). Strand β1, β2 and β5, helix α2 and α3, and the loops L2, L6 and 
L8 are involved in the contacts (Figure 28B). The interface is mainly built of 
hydrophobic residues with polar amino acids involved only in the periphery. The 
hydrophobic nature of the interface also explains why it was not possible to separate 
the two monomers even by high salt concentrations (up to 1M NaCl) (data not 
shown). 
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Figure 28. The Rap1GAP dimer interface.   A) Surface representation. All surface exposed 
residues of molecule A which are involved in the interface are shown in blue. 
B) Ribbon type presentation in the same orientation as in A showing in blue the 
secondary structure elements involved in the formation of the interface.  
C) Schematical representation of the amino acids contacts of molecule A (blue 
letters) and molecule B (red letters). Amino acids involved in polar interactions are 
shown as ball-and-stick representation.  
 
4.2.8 The catalytic centre 
Since different members of the Rap1GAP family are expected to interact with Rap1 in 
a similar way, it was reasoned that amino acids which contact Rap1 should be at 
least partially conserved. To identify the Rap1 binding interface, the distribution of 
conserved amino acids in the Rap1GAP structure was analysed. Tuberin was 
excluded from this alignment since it is a GAP for the small GNBP RheB and thus  
residues involved in binding are not necessarily conserved. A Rap1GAP surface 
presentation illustrating the distribution of conserved residues is shown in Figure 29. 
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Figure 29. Surface representation of Rap1GAP with front and back view showing in magenta all 
residues which are conserved among the Rap1GAP family. The position of several 
conserved amino acids is indicated. Ribbon plots indicate the orientation of the 
molecule. In A the conserved patch I is shown, in B the conserved patch II. 
The conserved residues cluster in two patches on the Rap1GAP surface. Patch I is 
larger and is located around helix α7 in the catalytic domain (Figure 29A). Also the 
conserved arginine R388 of helix α9 is in vicinity of this cluster. The second patch 
found on the opposite side of patch I consists of two hydrophobic residues 
(phenylalanine F345 and valine V336) and lysine K368.  
Since mutation of lysine K368 to alanine reduced the Rap1GAP activity only 2-fold 
(Figure 19), this residue was not expected to be involved in catalysis. Also 
phenylalanine F345 and valine V336 are no putative catalytic residues because they 
lack polar side-chains. Thus, it was concluded that patch II is probably not involved in 
Rap1 binding but might have a different function (see Discussion). It was 
hypothesised that Rap1 binds in the area of the conserved patch I around helix α7 
and α9. Residues important for catalysis have then to be located on this side of the 
Rap1GAP molecule. 
To further characterise the putative interaction site, an electrostatic surface was 
calculated (Figure 30). Rap1GAP has a calculated isoelectric point of 5,6, indicating a 
negative net charge at a physiological pH. However, no strong charges could be 
identified near patch I, the putative interaction side. A negatively charged surface 
spot was found in the catalytic domain and a positively charged surface spot in the 
dimerisation domain (Figure 30). These surface spots did not superimpose with the 
conserved residues in patch I or patch II, and their significance is unclear yet.  
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Figure 30. Electrostatic surface of Rap1GAP. Red colour indicates negative charge, blue colour 
positive charge at neutral pH. The surface was calculated using the program Grasp 
(Nicholls et al., 1993). 
It was rationalised that the catalytic centre of Rap1GAP and the site of Rap1 
interaction is close to those amino acids whose mutations reduce Rap1GAP activity 
dramatically. Therefore, lysine K194 and lysine K285 (see 4.1.4) were analysed in 
more detail. Strikingly, both lysines are part of the conserved surface patch I  
(Figure 29) and form contacts to other highly conserved residues (Figure 31).  
Lysine K194 is a residue of strand β6. In molecule A and C, it forms a salt bridge to 
aspartate D291 of helix α7 and a hydrogen bond to the carbonyl oxygen of 
asparagine N290 (Figure 31). Aspartate D291 in turn forms a hydrogen bond to 
histidine H267 in strand β9. Lysine K194, histidine H267 and aspartate D291 are 
completely conserved among Rap1GAPs and Tuberin (Table 3). These three amino 
acids seem to be important for the relative orientation of strand β6, β9 and helix α7.  
Lysine K285 is part of helix α7, like asparagine N290 and aspartate D291. Its 
ammonium group is involved in a salt bridge with glutamate E207 of helix α4 and in a 
hydrogen bond to the carbonyl oxygen of alanine A310 in loop L15 (Figure 31). Thus, 
lysine K285 appears to orient helix α7 relative to helix α4 and loop L15. Destroying 
this interaction by mutating lysine to alanine leads to a dramatic decrease in 
Rap1GAP activity. Since the ammonium group of lysine K285 is involved in a network 
of polar contacts, it is rather unlikely that it contributes to catalysis. 
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Figure 31. Ribbon type presentation of the Rap1GAP catalytic domain showing the 
involvement of lysine K194 and lysine K285 in a network of polar interactions. 
Hydrogen bonds and ionic interactions are represented by dashed lines. 
Additionally, surface exposed residues of helix α7 (coloured in purple) are depicted. 
The analysis of conserved residues in the Rap1GAP family and the examination of 
lysines K194 and K285 indicated that the catalytic centre of Rap1GAP and the site of 
Rap1 interaction is likely to be around helix α7. This helix is from hereon referred to 
as Rap1 interaction helix. 
Surprisingly, both lysines are solvent exposed in molecule B and do not make the 
contacts described above. This might reflect a certain flexibility of helix α7. It should 
also be mentioned that molecule A and C have a crystallographic contact close to 
helix α7 which is not present in molecule B.  
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4.3 The hydrolysis mechanism of Rap1GAP 
Based on the Rap1GAP structure, new constructs and point mutants were designed 
to elucidate details of the GAP mechanism. 
 
4.3.1 Dimerisation and Rap1GAP function 
Rap1GAP eluted as a dimer from gel filtration and two dimers were observed in the 
asymmetric unit of the crystal. It was asked whether dimerisation is a prerequisite for 
GAP function. Thus, it was intended to disrupt the dimer interface by targeted 
mutagenesis. Since the interface is built of mainly hydrophobic residues, it was 
reasoned that the introduction of charged residues might disrupt dimerisation. Thus, 
two central amino acids of the Rap1GAP interface, phenylalanine F100 and 
leucine L173 were exchanged to glutamate generating four negatively charged 
residues in the interface (Figure 32). 
 
Figure 32. Ribbon type presentation of the Rap1GAP dimer interface. Phenylalanine F100 and 
leucine L173 (white in molecule A, black in molecule B) were substituted with a 
glutamate to disrupt dimerisation. 
The Rap1GAPF100E,L173E double mutant eluted primarily as a monomer in size 
exclusion chromatography showing that dimerisation was indeed inhibited by the 
mutations. It did however not elute as a clear single peak but appeared also in 
fractions of smaller molecular weight (data not shown) indicating that the amino acid 
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substitutions partially destabilised or unfolded the protein. However, in a multiple-
turnover GAP assay using 100 µM Rap1•GTP as substrate, this mutant showed only 
a marginally reduced activity compared to Rap1GAP wild-type (Figure 33). It can be 
concluded that dimerisation is not important for the GAP reaction. 
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Figure 33. Mutational analysis of the Rap1GAP interface mutant and of the Rap1GAP catalytic 
domain. Initial rates of Rap1GAP stimulated GTP hydrolysis in Rap1•GTP were 
measured at 20 °C using a Rap1•GTP concentration of 100 µM and HPLC analysis 
and plotted in a bar diagram. The explicit kobs values at the respective GAP 
concentration are indicated in B.  
 
4.3.2 Involvement of both domains in the GAP mechanism 
The catalytic domain is much higher conserved than the dimerisation domain in the 
Rap1GAPs family. Furthermore, lysines K194 and K285 which most dramatically 
affected Rap1GAP activity when mutated to alanine are both located in the catalytic 
domain, and Tuberin has homology only to the catalytic domain. This implies that 
primarily the catalytic domain is involved in Rap1GAP activity. However, the R388A 
mutation reduces the affinity for Rap1 (Brinkmann, 2000) and arginine R388 is a 
surface exposed residue of the C-terminal helix α9 (Figure 34). This helix has many 
contacts to the dimerisation domain. This suggests that also residues outside the 
catalytic domain might be involved in Rap1GAP function.  
To test whether the catalytic domain in combination with arginine R388 preserves 
Rap1GAP activity, a construct was prepared containing the complete catalytic 
domain and parts of the C-terminal helix ending with arginine R388 (Rap1GAP188-388). 
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This protein could be prepared as GST fusion but showed no Rap1GAP activity. 
Upon removal of GST, the protein precipitated indicating that it might not be properly 
folded. Thus, no conclusion could be drawn from this construct.  
It was postulated that the interaction between helices α3 and α9 which are N-terminal 
and C-terminal of the catalytic domain, respectively, might stabilise the catalytic 
domain. Therefore, a new construct (Rap1GAP183-398) containing parts of both helices 
was prepared (Figure 34). This construct was highly soluble, did not precipitate upon 
removal of GST and eluted as a monomer in size exclusion chromatography. 
 
Figure 34. The Rap1GAP183-398 construct including the catalytic centre around helix α7. Arginine 
R388 on helix α9 is expected to bind to Rap1. The position of helix α9 is stabilised 
by hydrophobic interactions with helix α3. 
Rap1GAP183-398 was tested in the standard Rap1•GTP hydrolysis assay (Figure 33) 
and showed a residual Rap1GAP activity. However, at least a 1000-fold 
concentration of GAP was required in comparison to wild-type to stimulate GTP 
hydrolysis to a similar extent (Figure 33B). 
To find out whether Rap1GAP183-398 is folded, a CD spectrum (Figure 35) was 
recorded. The analysis of the CD spectrum predicted that the protein contained 28% 
β-strands, in good agreement to what is calculated from the structure. The helix 
proportion of Rap1GAP183-398 predicted from CD analysis to be 18% is somewhat less 
than what is expected from the structure (32%). 
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Figure 35. CD spectrum of Rap1GAP183-398 and data evaluation (3.3.17). The measured curve 
is shown in black, the fitted curve in red. 
These results indicate that the central β-sheet of the catalytic domain and thus the 
core is folded. Some helical elements, likely the peripheral helices, may not be 
correctly folded.  
Therefore, it is concluded that the catalytic domain alone is not sufficient for full 
Rap1GAP activity and that the dimerisation domain is required either for correct 
folding or correct positioning of the peripheral helices, especially helix α9 (see also 
Discussion). 
 
4.3.3 Role of helix stabilisation for Rap1GAP function 
The structure revealed that lysine K194 and K285 in molecule A and C are both 
involved in stabilising helix α7, the putative interaction helix (Figure 31). To confirm 
that stabilisation of this helix is important for Rap1GAP activity, the interaction 
partners of lysine K194 and lysine K285 were mutated to alanine, and the GAP 
activity of the mutants determined in a Rap1•GTP standard hydrolysis assay. 
Lysine K285 is involved in an ionic interaction with glutamate E207 and a hydrogen 
bond with the main chain oxygen of alanine A310. The E207A mutant shows a 
relatively mild reduction in activity compared to the K285A mutant (Figure 36), which 
can be attributed to the fact that lysine K285 is still stabilised by the main chain 
contact to alanine A310 (Figure 31).  
Lysine K194 forms a salt bridge to aspartate D291. The activity of the D291A mutant 
was analysed in the standard GAP assay, and nearly no stimulation of GTPase 
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activity was detected. Aspartate D291 interacts additionally with histidine H267. The 
H267A mutation also leads to a dramatically reduced GAP activity (Figure 36).  
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Construct kobs / sec-1 [GAP] kobs(wt) / kobs 
Wt 3,8 70 nM 1,0 
E207A 0,69 300 nM 5,5 
H267A 0,019 8000 nM 200 
D291A 0,0017 30000 nM 2200 
R286A 0,85 70 nM 4,5 
H287A 0,057 4000 nM 67 
N290A no activity 30000 nM - 
Figure 36. Mutational analysis of residues in and around helix α7. GAP activity was measured 
as described in the legend of Figure 33. The concentration of GAP used in the 
experiments is indicated.  
 
4.3.4 The catalytic residue 
Since stabilisation of the interaction helix is crucial for Rap1GAP activity, it was asked 
whether this helix might contain the catalytic residue of Rap1GAP. Therefore, all 
surface exposed conserved residues in the interaction helix were mutated to alanine 
(arginine R286, histidine H287, asparagine N290), and the activity of the mutants 
was analysed in the standard hydrolysis assay (Figure 36).   
The R286A mutant has a 4-fold reduced activity using 100 µM Rap1•GTP, similarly 
as described in 4.1.3. Histidine H287 is rather buried, and the H287A mutant has a 
dramatically reduced activity. Finally, the surface exposed asparagine N290 did not 
show any stimulation of GTPase activity in Rap1•GTP when mutated to alanine.  
To follow a single reaction cycle of GTP hydrolysis, a previously established 
fluorescence assay was applied (Kraemer et al., 2002). This assay monitors the 
association of Rap1GAP to fluorescently labelled Rap1•GTP leading to an increase 
Results  
74 
in fluorescence, and, after GTP hydrolysis, the concomitant dissociation of the 
complex resulting in a decrease of the fluorescence back to the basis level.   
The previously described reaction course for Rap1GAP wild-type (Kraemer et al., 
2002) could be confirmed (Figure 37). For the R286A mutant, the hydrolysis reaction 
was three-fold slower than for the wild-type, similar to what was observed in the 
multiple-turnover assay (Figure 36). This confirms that arginine R286 is not a residue 
of central importance in catalysis, in contrast to the arginine fingers of RasGAP, 
RhoGAP and RabGAP (Vetter and Wittinghofer, 2001). No association with 
Rap1•GTP was seen for the H287A mutant. However, surprisingly, association but 
no dissociation was observed for the N290A mutant (Figure 37).  
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Figure 37. Fluorescence based GAP assay with Rap1GAP and single point mutants of residues 
in the interaction helix. The reaction of 1 µM Rap1-Aedans•GTP with 25 µM Rap1GAP 
or the indicated Rap1GAP mutants was followed in the fluorescence stopped-flow 
assay as described in 3.3.16.1.    
The affinity of Rap1GAP wild-type to Rap1-Aedans•GTP under similar reaction 
conditions was previously found to be 14 µM (Kraemer et al., 2002). To examine 
whether the N290A mutation led to a decreased affinity for Rap1, the fluorescence 
assay was employed using varying concentrations of Rap1GAPN290A (Figure 38A). 
Observed rate constants were determined and plotted against the concentration of 
Rap1GAPN290A (Figure 38B), and the slope of the straight line corresponding to kon 
was fitted to be 0,32 sec-1•µM-1 (see Appendix). The koff rate was determined to be 
1,1 sec-1 by preparing a fluorescent Rap1-Aedans•GTP•Rap1GAPN290A complex and 
following the displacement of fluorescently labelled Rap1•GTP upon addition of an 
excess non-labelled Rap1•GTP (Figure 38C). Using KD = koff/kon, a KD of 3 µM was 
calculated (see also 7.2.1).   
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Figure 38. A) Determination of N290A affinity to Rap1•GTP. The binding reaction of 1 µM 
Rap1-Aedans•GTP with increasing concentrations of Rap1GAPN290A was monitored 
using stopped-flow.    B) Plotting the observed rate constants and fitting them to a 
linear equation results in a slope of 0,32 sec-1·µM-1 which corresponds to the kon.    
C) Determination of koff. 2 µM Rap1-Aedans•GTP and 20 µM Rap1GAPN290A were 
mixed with 200 µM non-labelled Rap1•GTP. The determined rate constant 
corresponds to koff and is 1,1 sec-1. With a kon of 0,32 sec-1·µM-1, a KD of 3,4 µM is 
derived.   D) Determination of KD by equilibrium titration. Plotting the maximal 
amplitudes in A and fitting them to a quadratic equation results in a KD of 2,4 µM. 
Since there is no complex dissociation, an alternative approach to determine KD 
could be applied by using an equilibrium titration equation (see Appendix). The 
amplitudes of the fluorescent transients (Figure 38A) were plotted against the N290A 
concentration and fitted to a quadratic binding equation (Figure 38D, see 7.2.2). 
Using this method a KD of 2,4 µM was obtained. 
In summary, the affinity of the Rap1GAPN290A mutant for Rap1•GTP is around 3 µM 
which is even higher than the wild-type affinity. This clearly implies that asparagine 
N290 is not involved in the binding to Rap1 but is directly involved in catalysis. 
Therefore, Rap1GAP constitutes the first example of a GAP which provides a 
catalytic asparagine to stimulate GTP hydrolysis in a GNBP. 
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4.3.5 Binding to a transition state analogue of GTP hydrolysis 
AlFx along with GDP (or ADP) is a known mimic of the transition state for many 
phosphoryl transfer enzymes such as myosin and Gα subunits of heterotrimeric 
G proteins (Chabre, 1990). It has been shown that aluminium fluoride binds to Ras-
like proteins only in the presence of their respective GAPs (Ahmadian et al., 1997b; 
Mittal et al., 1996; Graham et al., 1999), thus demonstrating that the active site of 
Ras-like proteins needs to be complemented by residues from GAP.  
To prove that asparagine N290 is directly involved in catalysis, the association of 
Rap1GAP with fluorescently labelled Rap1•GDP•AlF3 was followed by stopped-flow 
measurements. As shown in Figure 39, wild-type Rap1GAP indeed associates with 
Rap1•GDP•AlF3 leading to an increase in the fluorescence signal. The association is 
slow, similar to what is seen for Ras and Rho proteins (A. Wittinghofer, unpublished). 
While the R286A mutant also associates but shows a smaller fluorescence amplitude 
on complex formation, no association is seen for the N290A mutant (Figure 39). This 
shows unambiguously that asparagine N290 is directly involved in the catalytic 
process by stabilising the transition state of GTP hydrolysis. 
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Figure 39. Stabilisation of the transition state of GTP hydrolysis. Complex formation between 
Rap1•GDP and Rap1GAP is measured as a time-dependent increase of fluorescence, 
and is dependent on the presence of aluminium fluoride. While the R286A mutant 
shows complex formation with a decreased amplitude, no complex formation is 
observed for the N290A mutant. 
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4.3.6 Other important residues in Rap1GAP 
The region around asparagine N290 was more closely examined to find other 
important residues involved in catalysis in Rap1GAP (Figure 40).  
 
Figure 40. Stereo view of the electron density around asparagine N290. In direct vicinity of 
asparagine N290, the completely invariant phenylalanine F313 is located.  
Indeed, close to asparagine N290, a completely conserved phenylalanine 
(phenylalanine F313) was found. This phenylalanine is linked to the helix α7 through 
the interaction of lysine K285 and the carbonyl oxygen of alanine A310 (Figure 31). 
Phenylalanine F313 was mutated to alanine. The activity of the mutant was followed 
in the multiple-turnover assay and the fluorescence assay (Figure 41). In the multiple-
turnover assay, an 8-fold reduced activity was found at a Rap1•GTP concentration of 
100 µM (Figure 41A). Also in the fluorescence assay, a clearly reduced activity could 
be observed (Figure 41B). Since phenylalanine does not possess a putative catalytic 
function, it can be assumed that it is either involved in binding to Rap1, in positioning 
asparagine N290 for catalysis or in influencing the properties of the catalytic 
asparagine. 
The R388A mutation in Rap1GAP was previously found to reduce the affinity for 
Rap1 (Brinkmann et al., 2002). This mutant was also tested in both hydrolysis assays 
(Figure 41). In agreement with previous data (4.1.3), the mutant has a 4-fold reduced 
activity at a Rap1•GTP concentration of 100 µM. Surprisingly, nearly no signal was 
observed for the R388A mutant in the fluorescence GAP assay (Figure 41). This 
suggests that the fluorescence change depends on an interaction between 
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arginine R388 and a residue close to cysteine C86 in Rap1 where the fluorophore is 
attached or the fluorophore itself (see Discussion). 
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Figure 41. A) Multiple turnover analysis of Rap1GAPF313A and Rap1GAPR388A mutants as 
described in the legend of Figure 33.   B) Fluorescence GAP assay with 
Rap1GAPF313A and Rap1GAPR388A, shown in comparison to wild-type as described in 
the legend of Figure 37.  
 
4.3.7 Role of the carboxamide for GAP activity 
Rap1GAP is the only known GAP which provides a catalytic asparagine to the 
GNBP, and Rap1 does not have a catalytic glutamine. It was asked whether the 
missing carboxamide in the N290A mutant can principally be substituted by a 
glutamine on position 61 of Rap1. Therefore, this reaction was set up by using the 
Aedans labelled Rap1T61Q mutant together with the Rap1GAPN290A mutant and 
measuring the fluorescence in a long-term stopped-flow experiment (t= 500 sec).  
Surprisingly, 25 µM Rap1GAPN290A could stimulate GTP hydrolysis in 
1 µM Rap1T61Q•GTP with an observed rate of 0,16 min-1 (Figure 42). The rate of non-
stimulated GTP hydrolysis of the Rap1T61Q mutant at 10 °C was determined to be 
5,2·10-4 min-1 by standard HPLC measurements (data not shown). Thus, the 
stimulated reaction is 300-fold faster than the non-stimulated reaction, while for wild-
type Rap1 no acceleration of GTP hydrolysis was observed in this time-frame.   
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Figure 42. Fluorescence GAP assays. The reaction of 1 µM Rap1T61Q-Aedans•GTP or Rap1 
wild-type with 25 µM Rap1GAPN290A was monitored using stopped-flow as described 
in 3.3.16. Since the reaction was followed over 500 sec in this setup, not enough 
data point could be gathered in the first milliseconds to visualise the fluorescence 
increase upon mixing. 
To determine the affinity of Rap1GAPN290A to Rap1T61Q, the same approach as for 
Rap1 wild-type was employed. Maximal amplitudes for equilibrium titration 
experiment were obtained by measuring the fluorescence in a time range of 1 sec 
upon mixing, where no GTP hydrolysis is expected (Figure 43A,C). Since the 
Rap1T61Q•GTP•Rap1GAPN290A complex dissociates over time due to GTP hydrolysis, 
koff could not be obtained by a displacement reaction. Thus, koff was determined by 
plotting the observed rates against the concentration of Rap1GAPN290A and 
determining the intercept with the y-axis (Figure 43B, for deduction of the formula see 
Appendix). 
The results are summarised in Figure 43D. kon was determined to be 0,65 sec-1·µM-1, 
and koff to be 16 sec-1 , resulting in a KD of 25 µM. In comparison to Rap1 wild-type, 
the kon rate is in a similar range (0,32 sec-1·µM-1). However, koff is explicitly higher 
(1,1 sec-1 for wild-type). By fluorescence titration, the KD was determined to be 15 µM 
which is slightly lower than what is derived from the association kinetics.  
Assuming a KD of 20 µM, the reaction shown in Figure 42 is only to 60% saturated. 
This indicates that the observed rate is lower than the maximal rate. It can be 
concluded that Rap1GAPN290A accelerates the intrinsic reaction of Rap1T61Q more 
than 300-fold. 
This result shows that a carboxamide in Rap1 in position 61 can indeed substitute 
partially for the catalytic asparagine N290. However, it seems that glutamine Q61 can 
not be positioned accurately since the GTPase stimulation is still at least 500-fold 
reduced in comparison to the wild-type system. 
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Figure 43. Determination of Rap1GAPN290A affinity to Rap1T61Q•GTP. A) 2 µM Rap1T61Q-
Aedans•GTP was 1:1 mixed with various concentrations of Rap1GAPN290A. The 
fluorescence was monitored using stopped-flow as described in 3.3.16. B) Plotting 
the observed rate constants and fitting them to a linear equation results in a slope of 
0,65 sec-1·µM-1 corresponding to kon and an intercept with the y-axis of 16 sec-1  
corresponding to koff.    C) Determination of KD by equilibrium titration.  Plotting the 
maximal amplitudes in Figure 43A and fitting them to a quadratic equation results in 
a KD of 15 µM.    D) Comparison of kon and koff rates and the KD for Rap1GAPN290A with 
Rap1 wildtype and Rap1T61Q. 
 
4.3.8 Implications for Tuberous sclerosis  
Tuberin is a GAP for the small GNBP RheB. Loss of function mutations in the Tsc2 
gene lead to Tuberous sclerosis, a disease characterised by benign tumours. Single 
point mutations have been found in the GAP domain of Tuberin in Tuberous sclerosis 
patients (Maheshwar et al., 1997; Au et al., 1998; Jones et al., 1999; Dabora et al., 
2001) (Table 3). The sites of these mutations, indicated in the Rap1GAP catalytic 
domain, are shown in Figure 44. 
Most of the mutations described cluster in the core of the catalytic domain and most 
likely destabilise the protein. Mutations Y1549C in strand β6 (Rap1GAP numbering), 
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Y1650C and N1651S in strand β10, P1675L in strand β11, D1690Y in strand β12 and 
P1709L in strand β13 belong to this kind of mutations.  
Mutation N1681K is located in loop L16 which is not completely defined in the 
Rap1GAP structure. Also mutation A1712D is located in a loop (L18 in Rap1GAP). 
Since these mutations are rather far away from the putative RheB binding interface, it 
is difficult to predict their effect on Tuberin function.  
Mutation L1594M is located in the long loop L12. It is in vicinity of the catalytic centre 
and one might speculate that it is involved in RheB binding (see also Discussion). 
R1576 of Tuberin corresponds most likely to the surface exposed highly conserved 
arginine R388 in Rap1GAP (Table 3). As already discussed (see 4.3.6), it is located 
in helix α9 and its mutation in Rap1GAP leads to a reduced affinity for Rap1 
(Brinkmann et al., 2002). R1576 was found to be mutated to proline or glutamine in 
tuberous sclerosis patients. The R388P mutant of Rap1GAP has an even more 
reduced activity than the R388A mutant (Figure 44). Since arginine R388 is not in 
direct vicinity but on the same face as the catalytic asparagine, it is reasonable to 
assume that it constitutes to the binding interface with RheB (see Discussion). Thus, 
mutations in arginine R388 in Rap1GAP and most likely the R1576P/Q mutations in 
Tuberin interfere with binding to the small GNBP.  
 
Figure 44. A) Ribbon type presentation of Tuberin mutation sites which are found in tuberous 
sclerosis patients (see Table 3), based on the Rap1GAP structure.    B) Standard 
HPLC measurement using standard conditions as described in the legend of Figure 
33. 70 nM of Rap1GAP wild-type and of the Rap1GAPR388P mutant were used and 
60 µM for Rap1GAPN290K. 
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Tuberin mutations N1643K (Maheshwar et al., 1997; Jones et al., 1999) and N1643I 
(Au et al., 1998) can be most easily explained by analogy to Rap1GAP. Asparagine 
N1643 in Tuberin is homologous to the catalytic asparagine N290 in Rap1GAP and 
the equivalent mutations in Rap1GAP render the protein either completely inactive 
(N290K) (Figure 44) or insoluble (N290I) (data not shown). The loss of the catalytic 
asparagine in Tuberin clearly implies that patients bearing this mutation can not 
down-regulate RheB. 
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5 Discussion 
Members of the Rap family do not possess a catalytic glutamine which is essential for 
GAP mediated GTP hydrolysis in nearly all other GNBPs examined so far. In this 
work, the reaction mechanism and the structure of Rap1GAP were examined.  
By mutational analysis it was shown that Rap1GAP does not use an arginine finger. 
However, two lysine residues were identified, whose mutations dramatically reduced 
Rap1GAP activity. The X-ray structure of the Q204A Rap1GAP mutant was solved 
and showed two Rap1GAP dimers in the asymmetric unit. Each monomer consists of 
two domains, one involved in dimerisation of Rap1GAP, which was named the 
dimerisation domain, and one in which the previously identified lysines were located, 
which was named the catalytic domain. Rap1GAP has a completely novel GAP fold, 
but the catalytic domain shows structural similarity to the G domain of small GNBPs. 
Both lysines described above are involved in polar interactions around the putative 
Rap1 interaction helix whose primary sequence is highly conserved in the Rap1GAP 
family. When the interaction partners of these lysines were mutated, Rap1GAP 
activity is also strongly reduced. Asparagine N290 in the interaction helix was 
demonstrated to be the crucial catalytic residue, since mutating it to alanine 
completely eliminated Rap1GAP activity without interfering with the binding to Rap1. 
Furthermore, in contrast to wild-type, the N290A mutant cannot bind to a transition 
state analogue of GTP hydrolysis. The importance of a carboxamide in GAP 
mediated GTP hydrolysis was demonstrated since the N290A mutant of Rap1GAP 
could at least partially stimulate the activity of a Rap1 mutant in which a catalytic 
glutamine was introduced by a site-directed mutation. 
 
5.1 Dimerisation and role of two domains in Rap1GAP 
Rap1GAP eluted as dimer from gel filtration and two dimers were observed in the 
asymmetric unit (Figure 27). Since Rap1GAP is the first dimeric GAP described to 
date it was therefore of interest to analyse dimerisation in more detail. 
A monomeric Rap1GAP retained in vitro Rap1GAP activity comparable to wild-type 
(Figure 33). This result was in agreement with the identification of the catalytic 
asparagine and thus the catalytic centre of Rap1GAP in the catalytic domain which is 
more than 40 Å away from the dimerisation interface (Figure 27). Therefore, it is not 
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expected that Rap1 has contacts with the second Rap1GAP molecule during 
catalysis. It was therefore asked whether the observed dimer might be an artefact of 
the crystallisation condition or the construct chosen.  
Several arguments speak in favour of Rap1GAP existing as a dimer in the cell. (1) At 
physiological salt concentrations, the Rap1GAP catalytic domain elutes as a dimer in 
size-exclusion chromatography. It elutes as a single peak indicating that the dimer is 
rather stable. (2) In a yeast-two-hybrid screen, full-length Rap1GAP was found to 
interact with itself (H. Bos, personal communication). This shows that dimerisation is 
not an artefact of the chosen construct. (3) The dimer interface contains many 
hydrophobic residues (Figure 28). Since protein aggregation via the hydrophobic 
interface might be expected, this observation suggests that in the cell an interaction 
partner is needed. In fact, aggregation was already a problem for bacterial expressed 
protein since a major fraction of the expressed protein turned out to be insoluble and 
still a portion of the soluble protein was associated with the bacterial chaperone 
GroEL (Brinkmann, 2000). However, this association was not observed when the 
dimerisation mutant with two charged residues in the hydrophobic interface was 
expressed. This indicates that the hydrophobic Rap1GAP interface is likely 
associated with chaperone binding, aggregation and misfolding of the protein. 
It can only be speculated about the role of dimerisation in the cell. The Rap1GAP 
dimer might provide a functional scaffold for a complete module of signal transduction 
components which was already described for other signal-transduction systems 
(Pawson and Saxton, 1999). This would be in agreement with the original Rap1GAP 
purification protocol in which a Rap1GAP activity was purified from bovine brain 
cytosol as a 250-400 kD complex (Kikuchi et al., 1989). Alternatively, the dimer might 
supply two binding sites for an interaction partner for example at the membrane to 
increase the local concentration and thus the avidity for this putative partner. A 
similar phenomenon was described for the tetrameric lac repressor which needs two 
independent binding sites at the DNA to bind with high avidity to the target sequence 
(Oehler et al., 1994) and for many other DNA binding proteins.  
Both Rap1GAP domains are necessary for GAP activity (Figure 33). The catalytic 
domain contains the catalytic asparagine and a network of interactions stabilising the 
interaction helix (Figure 31). However, the role of the dimerisation domain is not so 
evident. 
As shown in this and in previous work (Figure 41 and Brinkmann et al., 2002), 
arginine R388 of helix α9 is likely to be involved in Rap1 binding. It is completely 
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surface-exposed and the R388A mutation reduces the affinity to Rap1 (Brinkmann et 
al., 2002). Furthermore, the R388P mutant which presumably interferes completely 
with the arrangement of helix α9 has nearly no GAP activity (Figure 44). Thus, 
residues of helix α9 seem to be involved in Rap1 binding. In contrast, residues of the 
dimerisation domain are not located close to the catalytic asparagine or even on the 
same side (Figure 27). Thus, no direct contact between Rap1 and the dimerisation 
domain is expected during catalysis. However, helix α3 and strand β1 of the 
dimerisation domain have many hydrophobic contacts with helix α9 which likely 
influence the position of helix α9. Thus, the role of the dimerisation domain might be 
the correct positioning of helix α9.  
Tuberin has sequence homology only to the catalytic domain including parts of the 
C-terminal helix α9 although no extensive homology is seen in the latter part 
(Table 3). Since experiments in our laboratory indicate that the isolated GAP domain 
of Tuberin has no GAP activity towards RheB under standard conditions 
(P. Chakrabarti, unpublished), it might be speculated that other parts of Tuberin or 
Hamartin might have a similar role as the Rap1GAP dimerisation domain in 
positioning the equivalent of the C-terminal helix α9. 
  
5.2 Interacting partners of Rap1GAP 
Gα proteins of heterotrimeric G proteins were described as interaction partners of 
Rap1GAP (Meng et al., 1999; Jordan et al., 1999; Mochizuki et al., 1999). In full-
length Rap1GAP, a sequence stretch comprising 74 amino acids precedes the 
N-terminus of the construct crystallised. This stretch was shown to interact with the 
Gα subunits of Gαz (Meng et al., 1999). In RapGAPII, it contains the GoLoco motif 
(Mochizuki et al., 1999) which binds in the nucleotide binding pocket of Gαi and 
makes direct contacts with the GDP α- and β-phosphate (Kimple et al., 2002). The 
interaction with Gαi relocalises RapGAPII from the cytosol to the membrane 
concomitant with a reduction of cellular Rap1•GTP. Thus, it is expected that a 
Rap1GAP dimer can interact simultaneously with one or two Gα proteins and 
Rap1•GTP. Since Rap1 and Gα proteins are both membrane-bound one would 
expect that the long axis of the Rap1GAP dimer will be in parallel to the membrane in 
this complex, since it would prove difficult otherwise to contact Gα and Rap1 to the 
same time. Clearly, only the structure of a Rap1GAP construct including the first  
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75 amino acids and the catalytic domain, ideally in complex with a Gα-protein, will 
clarify the exact mode of interaction. 
In a yeast-two-hybrid screen, the multi-domain protein AF-6 was found as putative 
interaction partner of Spa-1 and later shown to bind also to Rap1GAP (Su et al., 
2003). AF-6 contains a Ras-binding domain which interacts with Rap1 (Linnemann et 
al., 1999). Furthermore, genetic interaction experiments in Drosophila suggest that 
the AF-6 homologue Canoe and Rap1 act in the same molecular pathway (Boettner 
et al., 2000). It was proposed that AF-6 controls integrin-mediated cell adhesion by 
simultaneously recruiting Rap1 and Rap1GAP (Su et al., 2003). 
The binding sites for Rap1GAP and AF-6 were mapped (Su et al., 2003). It was 
proposed that the PDZ domain of human AF-6 binds to an internal peptide sequence 
in the catalytic domain comprised of amino acids 432IVF in Spa1 and 295VVF in 
Rap1GAP (Su et al., 2003). PDZ domains which belong to the most abundant protein 
domains in multi-cellular organisms most often interact with a short stretch 
(< 10 amino acids) at the C-terminus of target proteins (reviewed in Zhang and 
Wang, 2003). However, it was demonstrated that they can also interact with internal 
peptide sequences that adopt a β-hairpin structure (Hillier et al., 1999; Tochio et al., 
1999; Tochio et al., 2000). 
The identified peptide sequence in Rap1GAP is not in agreement with the solved 
structure since the proposed interaction motif is located five residues C-terminal of 
the catalytic asparagine in the interior of the Rap1GAP catalytic domain. It is without 
contact to the Rap1GAP surface and thus, no interaction with any partner protein can 
be expected. The in-vitro interaction observed is likely an artefact of the construct 
chosen by Su et al. which was generated by an in-vitro transcription and translation 
system. This construct starts in the middle of the dimerisation domain and ends in the 
middle of the catalytic domain and is therefore unlikely to fold. In line with this 
explanation, no interaction was observed between the bacterially expressed PDZ 
domain of AF-6 and the Rap1GAP construct described here (H. Rehmann, personal 
communication). Since it was reported that also full-length Spa-1 was 
co-immunoprecipitated with AF-6 and vice versa (Su et al., 2003), it still might be 
speculated that other domains of AF-6 and/or of Spa-1 are involved in this 
interaction.  
To locate binding sites for putative common interaction partner in the Rap1GAP 
family, the distribution of conserved amino acids on the surface can be analysed 
(Figure 29). A cluster of residues which are conserved in sequence among Rap1GAP 
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family members but not in Tuberin could be located opposite of the catalytic centre in 
the catalytic domain (Figure 29B). In the vicinity of this cluster in the dimerisation 
domain, a positively charged surface spot is located (Figure 30). This face of 
Rap1GAP family members might thus represent a putative interaction site with a 
negatively charged protein. 
A second putative interaction site might be located in loop L10 which contains 
glutamine Q204 in wild-type. This glutamine is completely conserved among 
Rap1GAPs. However, mutating it to alanine did not interfere with GAP function, and 
the Q204A mutant could be prepared in larger amounts, seemed to be more stable 
and crystallised better than the wild-type. The methyl group of alanine A204 points 
towards the interior of loop 10, an orientation which is certainly not possible for the 
long glutamine side-chain in wild-type (Figure 45). It is therefore expected that loop 
L10 is oriented differently in wild-type and the Q204A mutant. Since glutamine 204 is 
completely invariant and probably surface-exposed in wild-type and is neither 
required for catalytic activity nor structural integrity, one might expect another 
function, e.g. binding of a partner protein. 
 
Figure 45. Ribbon type presentation of the catalytic domain of Rap1GAP showing in ball-and-
stick alanine A204 in loop L10. The methyl side-chain of alanine A204 points to the 
interior of the loop, a position likely not compatible with a glutamine side-chain of 
the wild-type. 
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5.3 The novel GAP mechanism 
The mechanism of GAP-stimulated GTPase reactions on most Ras-like proteins 
involves two main residues. A glutamine is located on the GNBP, while the GAP 
apart from stabilising the catalytic machinery, very often supplies a so-called arginine 
finger (Scheffzek et al., 1998). Mutation of the glutamine in Ras, Rho and Ran almost 
completely eliminates the GTPase reaction (Der et al., 1986; Xu et al., 1997; 
Seewald et al., 2002). However, the importance of the arginine finger varies in the 
different systems. It is most important for Ras (Ahmadian et al., 1997c) and Rab 
(Albert et al., 1999), somewhat lower for Rho (Rittinger et al., 1997b; Rittinger et al., 
1997a), while Ran does not employ an arginine finger (Seewald et al., 2002), and its 
importance for ArfGAP is still debated (Goldberg, 1999; Mandiyan et al., 1999, see 
Introduction). 
In this work, the mechanism of Rap1GAP was explored which does not use an 
arginine finger but provides an asparagine for catalysis. In contrast to most other 
small GNBPs, Rap1 does not have a catalytic glutamine but a threonine residue at 
the equivalent position. This substitution reduces the intrinsic GTP hydrolysis rate 
(Frech et al., 1990). Threonine T61 is also not required for GAP stimulated GTP 
hydrolysis in Rap1 (Maruta et al., 1991 and P. Chakrabarti, unpublished). The small 
GNBP RheB whose GTPase reaction is accelerated by the Rap1GAP homologue 
Tuberin, has a glutamine at the equivalent position of glutamine Q61 in Ras, which is 
however not required for Tuberin stimulated GTP hydrolysis (Li et al., 2004). What 
might be the role of the catalytic asparagine in Rap1GAP ? 
Since asparagine is neutral at physiological pH – in contrast to the arginine finger - it 
can not provide positive charge to stabilise the transition state of GTP hydrolysis. 
This suggests that it has a different role, e.g. the positioning of the attacking water 
molecule.  
This assumption is supported by the analysis of the Rap1G12V mutant. In most 
examined GNBPs, mutations at the third position in the P loop, equivalent to glycine 
G12 of Ras, can not be down-regulated by GAPs, since any side-chain at this 
position interferes with the arrangement of the catalytic glutamine and the arginine 
finger in the transition state of GTP hydrolysis (Scheffzek et al., 1997; Rittinger et al., 
1997b). However, Rap1GAP can downregulate the Rap1G12V mutant (Brinkmann et 
al., 2002). Furthermore, RheB has an arginine residue at the equivalent position of 
glycine G12 in Ras and still can be activated by Tuberin. This indicates that the 
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catalytic asparagine will occupy a different position than the arginine finger in the 
RasGAP-Ras or RhoGAP-Rho system where no interference with a side-chain at the 
third position in the P loop will occur.  
Since the catalytic asparagine is necessary for binding to a transition state mimic of 
GTP hydrolysis (Figure 39), it is reasonable to assume that it will bind – directly or 
indirectly – to the aluminium fluoride and hence to the γ-phosphate during the real 
transition state. Direct binding could be mediated by a hydrogen bond from the side-
chain carboxamide to the terminal γ-phosphate oxygens. This would however place 
the asparagine in a similar position than the arginine finger which is unlikely to 
happen (see argumentation of the G12V mutant above). Indirect binding could be 
mediated by a hydrogen bond to the attacking water molecule which in turn is 
complexed by aluminium fluoride. In this case, the position of the asparagine would 
be in hydrogen bond distance to the attacking water molecule but rather in an 
extension of an axis built from the γ-phosphate and the attacking water molecule. At 
this position, no interference with a mutation in glycine G12 would be expected. Thus, 
it is proposed here, that the catalytic asparagine takes over the role of the catalytic 
glutamine in other GNBPs to position the attacking water molecule. 
What is the common theme of GAP catalysis ? Three components are essential for 
catalysis in all GNBP-GAP systems described to date. (1) A divalent metal ion has to 
be present for GTP binding and hydrolysis. Mg2+ and Mn2+ are both suitable and they 
are similarly octahedrally coordinated in the active site (Schweins et al., 1997). They 
counterbalance the negative charge of the nucleotide and arrange residues in the 
active site (Sprang, 1997). 
(2) The P loop is present in all system described. It is required for nucleotide and 
magnesium binding but has also a role in catalysis. The third and second-last residue 
of the P loop corresponding to glycine G13 and lysine K16 in Ras, respectively, form 
strong hydrogen bonds to the β-phosphate (Redfield and Papastavros, 1990). The 
main chain amid group of glycine G13 in Ras was proposed to promote catalysis by 
binding to the β-γ phosphate bridging oxygen (Maegley et al., 1996). Lysine K16 from 
the GKS motif of the P loop was proposed to stabilise the transition state of GTP 
hydrolysis by binding to the non-bridging β-phosphate oxygen (Allin et al., 2001). 
(3) All GAPs assist in positioning the attacking water molecule relative to the 
γ-phosphate. In Gα proteins and the small GNBPs with the exception of Rap1 and 
Sar1, this task is mediated by a catalytic glutamine present in the GNBP which is 
correctly positioned by the interaction with the arginine finger (Scheffzek et al., 1998). 
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In the complex of signal recognition particle with its receptor, the attacking water 
molecules are positioned by aspartate residues (Focia et al., 2004; Egea et al., 2004, 
see Introduction). A histidine is responsible for water positioning in Sar1 and most 
likely in EF-Tu (Cool and Parmeggiani, 1991; Berchtold et al., 1993; Zeidler et al., 
1995; Vogeley et al., 2001; Mohr et al., 2002). Finally it is proposed in this work, that 
in the case of Rap1 and RheB, an asparagine provided from the GAP positions the 
water. When a glutamine is reintroduced in Rap1 at position 61, the resulting 
Rap1T61Q mutant can be at least partially stimulated by the Rap1GAPN290A mutant 
which misses the catalytic asparagine (Figure 42). Thus, placing the attacking water 
at a position close to the γ-phosphate is a principle likely applied by all GNBPs.  
In most GNBPs but not in Ran and Rap1, a catalytic arginine is additionally supplied 
for catalysis. This arginine is thought to stabilise an associative or dissociative 
transition state (Scheffzek et al., 1997; Allin et al., 2001) or to assist in positioning the 
attacking water molecule by binding to the catalytic glutamine (Scheffzek et al., 1997; 
Rittinger et al., 1997b). As shown by Seewald et al. (2002) and in this work, however 
the arginine finger is not universally applied in all GAP systems. 
 
5.4 Proposed model of the Rap1GAP-Rap1 complex 
The interaction site with Rap1 was extensively mapped in this thesis by mutational 
analysis. It was shown that mutations in and around helix α7 whose sequence is 
highly conserved in the Rap1GAP family and Tuberin reduce the affinity or catalytic 
activity towards Rap1. The identified amino acids resulting in loss of activity when 
mutated to alanine could be classified in the following categories. (1) Amino acids 
which are involved in interactions stabilising helix α7. Glutamate E207, lysine K285, 
lysine K194, aspartate D291 and histidine H267 can be included here. (2) Surface-
exposed amino acids in helix α7, probably involved in Rap1 binding. Arginine R286 
and histidine H287 can be included here. (3) The catalytic residue, asparagine N290. 
(4) Residues likely to be involved in Rap1 binding which are not members of helix α7. 
Phenylalanine F313 and arginine R388 belong in this category.  
Residues of category 2, 3 and 4 can be used to predict the putative Rap1 interface 
since they are expected to directly contact Rap1. 
Several arguments should be considered before setting up an interaction model. In 
contrast to the arginine fingers of Ras and Rho, the catalytic asparagine of Rap1GAP 
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is not located in a flexible loop but at the end of helix α7 (Scheffzek et al., 1997; 
Rittinger et al., 1997b). The position of this helix is fixed by hydrogen bonds and ionic 
interactions although a certain flexibility of the helix could be deduced from 
molecule B in which the stabilising interactions are not observed. Nonetheless, it is 
not expected that major conformational changes will take place around helix α7, in 
contrast to the arginine finger loops of other GAPs (Scheffzek et al., 1997; Rittinger et 
al., 1997b).  
Arginine R388 is located in the C-terminal helix α9 which is proposed to be 
positioned by the dimerisation domain (see Discussion above and Figure 34). Since 
only few interactions are observed between the catalytic and dimerisation domain it 
can be argued that the relative position of the domains and thus of arginine R388 to 
the catalytic domain changes during Rap1 binding. 
The Rap1 structure, on the other side, was solved in the GppNHp bound state only in 
a complex containing RafRBD (Nassar et al., 1995). Alternatively, the structure of 
Rap2 which shows ~60% sequence identity to Rap1 was solved in the GTP and GDP 
bound state (Cherfils et al., 1997). Since the switch regions of small GNBPs are 
known to make contacts to GAPs and undergo major conformational changes upon 
GAP or effector binding (e.g. Scheffzek et al., 1998; Nassar et al., 1995) it is difficult 
to predict their exact conformation in the Rap1-Rap1GAP complex. Some predictions, 
however, can be made which Rap1 in the predicted complex should fulfil. 
Phenylalanine F64 of Rap1 should be involved in the interface since a mutation to 
alanine renders the resulting mutant completely insensitive to Rap1GAP (Brinkmann 
et al., 2002). Alanine A86 should be close to the interaction face since the fluorescent 
reporter group was attached at position 86 and is unquenched upon Rap1GAP 
binding (Kraemer et al., 2002). Furthermore, residue 86 of Rap1 is expected to be 
close to arginine R388 of Rap1GAP since the R388A mutant has an approximately 
4-fold reduced activity but does not show any fluorescence change in the fluorescent 
reporter assay (Figure 41). This argues that arginine R388 might be in direct vicinity 
of the fluorescent reporter group. Finally, the γ-phosphate should be freely accessible 
for asparagine N290, and asparagine should be able to position the attacking water 
molecule. Having defined these prerequisites, it was possible to find an arrangement 
in which all parameters described above are fulfilled (Figure 46).  
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Figure 46. Two opposing views of a model of the Rap1GAP•Rap1•GTP complex (pdb 
coordinates for Rap1 from the Rap1•GppNHp•RafRBD complex (PDB code 1C1Y). 
Rap1GAP is shown as ribbon type presentation in standard colours. Rap1•GTP is 
shown as a grey Cα worm in which the switches and the P loop are coloured in 
cyan. Selected residues are shown as ball-and-stick. The site of fluorophore 
attachment in Rap1 is shown as blue ball.   
In this model, asparagine N290 approaches the γ-phosphate from a similar position 
than the catalytic glutamine in Ras and could allow the positioning of the attacking 
water molecule. Switch I of Rap1 is in close vicinity to the interaction helix α7 of 
Rap1GAP and glutamate E37 of Rap1 contacts histidine H287 from the interaction 
helix which is known to dramatically reduce GAP activity when mutated to alanine 
(Figure 36, Figure 37). Switch I interacts also with loop L12 of Rap1GAP. In the 
equivalent loop of Tuberin, mutations were found in tuberous sclerosis patients 
(Figure 44). 
Phenylalanine F64 in switch II of Rap1 clashes with glutamate E207 of helix α4 and 
loop L15 containing alanine A310 in Rap1GAP. Mutations in this region of Rap1GAP 
in which also lysine K285 is located strongly reduce Rap1GAP activity (Figure 36). It 
could be speculated that this interaction will rearrange switch II and allows 
asparagine N290 to access into the active site.  
Phenylalanine F313 which is completely conserved in the Rap1GAP family and 
whose mutation interferes with Rap1GAP activity (Figure 40,Figure 41) is in van-der-
Waals contact to the P-loop of Rap1. 
Arginine R388 of Rap1GAP contacts the loop between strand β4 and helix α3 of 
Rap1 in which residue 86 and thus the site of fluorophore attachment is located. 
Mutations in arginine R388 to alanine could interfere locally with Rap1 binding which 
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would explain why no fluorescent signal can be observed for the R388A mutant 
(Figure 41). 
In summary, the model of the Rap1GAP-Rap1 complex presented here agrees well 
with all data gained from mutagenesis, kinetic and structural studies. Certainly, 
conformational changes will occur in Rap1 and Rap1GAP upon binding, especially in 
switch I and II of Rap1 which are not predicted in this model. Thus, the structure of 
Rap1GAP in complex with Rap1•GDP•AlF3 or a non-hydrolysable GTP analogue is 
ultimately needed. However, as long as no complex structure is available, the model 
described here might serve as a guideline for the development of further experiments. 
 
5.5 Implications for Tuberous Sclerosis and cancer 
Tuberous sclerosis is an autosomal dominant syndrome which is caused by 
mutations in the genes Tsc1 encoding Hamartin or Tsc2 encoding Tuberin 
(Kwiatkowski, 2003). The disease is characterised by the development of benign 
tumours, hamartomas, which are most often found in brain, skin, kidney and heart 
(Gomez et al., 1999). They are rarely malignant but cause neurological disorders and 
seizure due to their involvement in the brain.  
The development of tuberous sclerosis seems to follow in most cases the classical 
Knudson paradigm for tumour suppressor genes (Knudson, Jr., 1971). Initially, one 
loss of function germline mutation is present in either the Tsc1 or Tsc2 gene (first hit). 
Loss of heterozygosity leading to loss of function in the second allele will cause 
hamartoma development (Kwiatkowski, 2003). 
Tsc1 and Tsc2 form a complex in vivo. Recent findings in Drosophila have 
established a link between the Tsc complex, insulin signalling and the mTOR 
pathway (Figure 47) (reviewed in Manning and Cantley (2003), Li et al. (2004)). In 
this pathway, the Tsc complex acts as GAP towards the small GNBP RheB and 
suppresses mTOR signalling and cell growth. Upon signalling by growth factors, the 
Tsc complex becomes inactivated by phosphorylation and concomitantly RheB 
becomes activated. RheB promotes mTOR signalling and thus cell growth through a 
yet not identified mechanism. In the absence of a functional Tsc complex, mTOR 
signalling is switched on continuously, leading to uncontrolled cell growth.  
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Figure 47. The Tsc signalling pathway (from Li et al., 2004). Activation of the Akt-kinase by 
growth factors such as insulin leads to phosphorylation and concomitant 
inactivation of the Hamartin-Tuberin complex. Since this complex acts as GAP 
towards the small GNBP RheB, GTP bound RheB can accumulate and activates 
through an unknown mechanism the kinase mTOR which is a central regulator of 
cell growth. mTOR in turn regulates protein expression by inhibiting the initiation 
factor 4E-BP1 and by activation of the protein kinase S6K1. mTOR can be regulated 
also by cellular nutritient level but the role of Tsc1/Tsc2 in this regulation is unclear. 
Most of the mutations found in Tuberous sclerosis patients are deletions or non-
sense mutations in the Tsc2 gene (Dabora et al., 2001). However, also single point 
mutations were described in various parts of the Tsc2 gene many of which are 
located in the region homologous to the catalytic domain of Rap1GAP (Figure 44). 
Many of the mutations seem to cluster in or close to the hydrophobic core of the 
structure, and thus most likely destabilise the protein. However, in the case of the 
N1643K and N1643I mutation, the catalytic residue necessary for GAP function is 
mutated (Figure 44). This implies that the mutation of a single residue crucial for 
catalysis can induce Tuberous sclerosis. A similar case was described for the 
disease neurofibromatosis, in which a point mutation of the catalytic arginine in the 
RasGAP NF1 can induce the formation of benign tumours (Klose et al., 1998). In the 
case of tuberous sclerosis, it confirms that it is the up-regulated RheB in the mTOR 
pathway that leads to un-regulated cell growth. 
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Two further mutations in Tuberous sclerosis patients can be explained by the 
interaction model presented above (Figure 46). R1576Q/P in Tuberin corresponds to 
the surface exposed highly conserved arginine R388 in Rap1GAP which is located in 
helix α9 of the catalytic domain. The corresponding R388P mutation in Rap1GAP 
dramatically reduces GAP activity. In the interaction model, arginine R388 is 
proposed to interact with a loop between strand β4 and helix α3 of Rap1. Thus, the 
R1576Q/P mutation is likely to interfere with the binding of RheB to Tuberin.  
The L1594M mutation is proposed to be in a loop equivalent to loop L12 in Rap1GAP 
which in the interaction model is involved in binding to switch I of Rap1. Although this 
mutation does not seem to be so dramatic, it might also interfere with Tuberin binding 
to RheB. 
Recently, the Rap1GAP homologues Spa1 (Ishida et al., 2003) and E6TP1 (Gao et 
al., 2001a) have been described as tumour suppressor genes. It is expected that 
inactivating mutations in the Rap1GAP domain of Spa1 or E6TP1 will be identified in 
certain tumours. When these mutations are identified, the structure of Rap1GAP and 
the Rap1GAP-Rap1 model will help to explain the molecular details how these 
mutations might interfere with GAP function.  
 
 
5.6 Evolution of the Rap1GAP system 
Surprisingly, the catalytic domain of Rap1GAP showed structural similarity to the G 
domain, especially of small GNBPs as determined in a DALI homology search 
(Figure 25, Figure 26). The catalytic asparagine is positioned in a helix equivalent to 
the switch II helix α2 in Ras. This argues that Rap1 and the catalytic domain of 
Rap1GAP might have evolved from a common ancient GNBP. This GNBP might 
have stimulated its GTPase activity through transient dimerisation, similar to what is 
described for the signal recognition particle and its receptor (Focia et al., 2004; Egea 
et al., 2004) and what is proposed for the GNBPs GBP1 and IIGP (Prakash et al., 
2000; Uthaiah et al., 2003). The highly flexible switch II might have proven especially 
suitable to promote catalysis in the other GNBP. After gene duplication, one GNBP 
might have specialised as GAP and lost its ability to bind nucleotides accompanied 
by the loss of the P-loop and the rebuilding of switch I as seen in the case of 
Rap1GAP. 
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GAPs for Rap1 with the chain fold of the Rap1GAP catalytic domain are present from 
yeast to human. Schizosaccharomyces pombe but not Saccharomyces cerevisiae 
has a Tuberin homologue (Matsumoto et al., 2002) which is likely to activate the 
GTPase activity of the yeast RheB homologue Rhb1 responsible for regulation of cell 
growth (Mach et al., 2000). This might indicate that the first GAP of the Rap1GAP 
family was a Tuberin homologue since no protein in yeast exists with the combination 
of dimerisation and catalytic domain as described here for Rap1GAP. Alternatively, 
yeast might have lost its Rap1GAP homologue during evolution. Proteins with the 
typical Rap1GAP domain arrangement are described in Dictyostelium in which a 
Rap1GAP homologue was found (J. Faix, unpublished) and in the nematode 
Caenorhabditis elegans in which a Rap1GAP as well as Spa1 homologue were 
identified.  
However, also GAPs for Rap1 were described which do not have any sequence 
similarity to the Rap1GAP family. In Saccharomyces cerevisiae, the putative Rap1 
homologue Bud1 is involved in selection of the new budding site (Chant and 
Herskowitz, 1991). In contrast to Ras and Rap1, it contains an isoleucine at position 
61. Interestingly, the GAP for Bud1 which is called Bud2 has sequence homology to 
the RasGAP family and has also a putative arginine finger as judged from sequence 
comparison (Park et al., 1993). Likewise, the human GAPIP4BP has sequence 
homology to the RasGAP family, but GAP activity towards Ras and Rap1 has been 
described (Cullen et al., 1995). Unexpectedly, results in our laboratory indicate that 
the GAPIP4BP catalytic domain has appreciable GAP activity only towards Ras but not 
Rap1 (L.C. Polte and O. Daumke, unpublished). However, the full-length GAPIP4BP 
activates Ras and Rap1 with comparable rates. Furthermore, the GAP activity 
towards Ras seems to be dependent on the arginine finger whereas the GAP activity 
towards Rap1 is not (P. Cullen, unpublished). These observations indicate that 
GAPIP4BP uses a different mechanism to stimulate GTP hydrolysis in Ras and Rap1. It 
can be speculated that equivalent to the dimerisation domain of Rap1GAP, a second 
domain in GAPIP4BP is needed for full GAP activity towards Rap1.   
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7 Appendix 
7.1 Abbreviations 
Å  Ångström (0.1 nm) 
AU  Asymmetric unit 
Da  Dalton 
DNA  Deoxyribonucleic acid 
DTE  1,4-dithioerythritol 
EDTA  Ehtylendiamintetraacetat 
E. coli   Escherichia coli 
Fcalc, Fobs Structure factor amplitudes (calc: calculated, obs: observed) 
GAP  GTPase Activating Protein 
GDP  Guanosin diphosphate 
GEF  Guanine nucleotide exchange factor 
GMP  Guanosin monophosphate 
GNBP  Guanine Nucleotide Binding Protein 
GSH  Reduced glutathione 
GST  Glutathione-S-transferase 
GTP  Guanosin triphosphate 
HEPES 4-(2-Hydroxyethyl)-piperazin-1-ethan-sulfonic acid  
IAEDANS  (5-((((2-iodoacetyl) amino) ethyl) amino) naphthalin-1-sulfonic acid) 
IPTG  Isopropyl-β-D-1-thiogalactopyranosid 
kD  kilo Dalton 
λ  wavelength 
LRR  leucine rich repeat 
MME  Mono-Methyl-Esther 
MPD  2-Methyl-2,4-Pentandiol 
NCS  Non-crystallographic symmetry 
NMR  Nuclear magnetic resonance 
OD600  Optical density at 600 nm  
PEG  Polyethylene glykol 
PMSF  Phenylmethylsulfonylfluoride 
RBD  Ras binding domain 
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rmsd  Root-mean-square deviation 
SAD  Single wavelength with anomalous dispersion 
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SIMBI  signal recognition particle, MinD and BioD 
SeMet Seleno-L-Methionine  
SIRAS Single isomorphus replacement with anomalous scattering 
TCA  Trichloric acid 
TLS  translation, libration, screw-rotation displacement 
TRIS  Tris-(hydroxymethyl)-aminomethane 
TRAFAC Translation factor related 
 
 
For amino acids, the one and three letter code was used 
 
A Ala alanine  I    Ile isoleucine R Arg arginine 
C Cys cysteine K Lys lysine S Ser serine 
D Asp aspartate L Leu leucine T Thr threonine    
E Glu glutamate M Met methionine V Val valine 
F Phe phenylalanine N Asn asparagine W Trp tryptophane 
G Gly glycine P Pro proline Y Tyr tyrosine 
H His histidine Q Gln glutamine x any amino acid 
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7.2 Deduction of equations 
7.2.1 Determination of kon and koff via kobs 
The interaction of two proteins A and B in dynamic equilibrium is described in  
Figure 48. 
ABBA ⎯→⎯+ kon  
Figure 48. Two interacting proteins A and B in dynamic equilibrium. 
 
The differential change in concentration [AB] is described by Equation 11.  
 ][][][][ ABkBAk
dt
ABd
offon ⋅−⋅⋅=  Equation 11  
Concentration [A] is described by [A0] – [AB].  If [B0] >> [A0], [B] is ~ equal to [B0] 
(pseudo first order kinetics). Substituting these values in Equation 11 leads to 
Equation 12.  
)][(][][][][][])[]([][ 00000 offononoffon kBkABBAkABkBABAkdt
ABd +⋅⋅−⋅=⋅−⋅−⋅=  
 Equation 12 
or 
 [ ] [ ]( ) [ ] ][][ 000 BAkABkBkdtABd offoffon ⋅⋅=⋅+⋅+  Equation 13 
To solve the inhomogeneous differential Equation 13, the associated homogeneous 
differential Equation 14 has to be solved first. 
 [ ] [ ]( ) [ ] 00 =⋅+⋅+ ABkBkdtABd offon  Equation 14 
Rearranging variables in Equation 14 leads to Equation 15.  
 dtkBkAB
ABd
offon )][(][
][
0 +⋅−=  Equation 15 
 
 
⎯⎯←koff
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Integration of Equation 15 leads to Equation 16. 
 α+⋅+⋅−= tkBkAB offon )][(]ln[ 0  Equation 16 
or  
tkBktkBktkBk offonoffonoffon eeeeAB ⋅+⋅−⋅+⋅−+⋅+⋅− ⋅=⋅== )][()][()][( 000][ βαα  
 Equation 17 
in which β = eα. 
 
Equation 17 is one solution of Equation 14. To make it also the solution for 
Equation 13, [AB] in Equation 13 has to be replaced by Equation 18. 
 [ ]( ) [ ] [ ]00)][(0)][( 00 BAkekBkedtd offtkBkoffontkBk offonoffon ⋅⋅=⋅⋅+⋅+⋅ ⋅+⋅−⋅+⋅− ββ   Equation 18 
With ω = kon•[B0]+koff, Equation 18 can be simplified to Equation 19.  
 [ ] [ ] tofft eBAkedt
d ϖϖ βϖβ −− ⋅⋅−⋅⋅=⋅ 00  Equation 19 
 [ ] [ ] tofftt eBAkeedt
d ϖϖϖ βϖϖββ −−− ⋅⋅−⋅⋅=−⋅+ 00)(  Equation 20 
 [ ] [ ]00 BAkedt
d
off
t ⋅⋅=−ϖβ  Equation 21 
 [ ] [ ] dteBAkd toff ϖβ +⋅⋅⋅= 00  Equation 22 
Integration of Equation 22 leads to Equation 23.  
 [ ] [ ] ceBAk toff +⋅⋅⋅⋅= +ϖϖβ 00
1  Equation 23 
Equation 23 can be substituted in Equation 17. 
[ ] [ ] ttoff eceBAkAB ⋅−+ ⋅⎟⎠
⎞⎜⎝
⎛ +⋅⋅⋅⋅= ωϖϖ 00
1][  
 toff ec
BAk
AB ϖϖ
−⋅+⋅⋅= ][][][ 00  Equation 24 
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c can be determined from the starting conditions (t=0, [AB]=0) 
 c
BAkoff +⋅⋅= ϖ
][][
0 00  Equation 25 
c from Equation 25 can be substituted in Equation 24. 
 )1(
][][][][][][
][ 000000 tofftoffoff e
BAk
e
BAkBAk
AB ϖϖ ϖϖϖ
−− −⋅⋅⋅=⋅⋅⋅−⋅⋅=  Equation 26 
This expression for [AB] can be used to express [A] as 
 )1(
][][
][][][][ 0000
toff e
BAk
AABAA ϖϖ
−−⋅⋅⋅−=−=  Equation 27 
If only species AB and A are fluorescent, the observed fluorescence Γ can be 
described as in Equation 28. 
 
ttoffoff eYXe
ABkABk
AABA ϖϖϖλνϖλνλνλ
−− ⋅−=⋅⋅⋅⋅−−⋅⋅⋅−+⋅=⋅+⋅=Γ 00000 )()(][][][   
Equation 28 
in which λ is the fluorescence coefficient of species A and ν is the fluorescence 
coefficient of species AB. Thus, 
 off0on k][Bk +⋅==ϖobsk  Equation 29 
 
7.2.2 Fluorescence titration  
In equilibrium as described in Figure 48, KD can be described as  
 
][
][][
AB
BA
k
k
K
on
off
D
⋅==  Equation 30 
Substituting [A] with ([A0] – [AB]) and [B] with ([B0] – [AB]) and rearranging variables  
leads to Equation 31. 
 0 ][B ][A  [A·B] ) K  ][B  ][A (–  [A·B] 00D00
2 =⋅+⋅++  Equation 31 
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The meaningful solution of Equation 31 is Equation 32. 
][][
2
K  ][B  ][A 
2
K  ][B  ][A ][ 00
2
D00D00 BAAB ⋅−⎟⎠
⎞⎜⎝
⎛ ++−++=   Equation 32 
 
The observed fluorescence Γ can be described as in Equation 33. 
][])[]([][][ 0 ABABAABA ⋅+−⋅=⋅+⋅=Γ νλνλ ][][][ 0 ABA ⋅−+⋅= λνλ  
Equation 33 
in which λ is the fluorescent coefficient of species A and ν the fluorescent coefficient 
of species AB.   
If the fluorescence of species A is smaller than the fluorescence of species AB, then 
λ•[A0] is equal to the minimum fluorescence Γ min and ν•[A0] is equal to the maximum 
fluorescence Γmax. Substituting [AB] from Equation 32 and factoring out [A0] leads to 
Equation 34. 
0
00
2
D00D00
minmaxmin
][][
2
K  ][B  ][A 
2
K  ][B  ][A 
)(
A
BA ⋅−⎟⎠
⎞⎜⎝
⎛ ++−++
⋅Γ−Γ+Γ=Γ  
Equation 34 
 
This formula can be non-linearly fitted to obtain Γmin, Γmax and KD..   
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8 Zusammenfassung 
Rap1GAP ist das Gründungsmitglied einer Familie GTPase-aktivierender Proteine 
(GAPs) für das kleine Guaninnukleotid-bindende Proteinen (GNBP) Rap1. Diese 
Familie besitzt keine Sequenzgemeinsamkeit zu GAPs anderer GNBPs. Im 
Gegensatz zu fast allen anderen kleinen GNBPs hat Rap1 keinen katalytischen 
Glutaminrest, der sonst essentiell für die intrinsische und GAP vermittelte GTP-
Hydrolyse ist. In dieser Arbeit wurde die Struktur und der Reaktionsmechanismus 
von Rap1GAP untersucht.  
Die meisten GAPs stellen dem GNBP ein katalytisches Arginin zur Verfügung. In 
Rap1GAP konnte jedoch durch Mutationsanalyse kein katalytischer Argininrest 
identifiziert werden. Daraufhin wurde die Struktur eines katalytischen Fragments von 
Rap1GAP durch Röntgenstrukturanalyse bis zu einer maximalen Auflösung von 
2,9 Å aufgeklärt. Das Phasenproblem wurde durch Selenomethionin-substituierte 
Kristalle und ein SIRAS-Phasierungsprotokoll gelöst. Ein molekulares Modell wurde 
erstellt und bis zu einem Rcryst-Wert von 23,4% und einem Rfree-Wert von 27,5% 
verfeinert. 
In vorangegangenen Gelfiltrations-Experimenten wurde Dimerisierung von Rap1GAP 
beobachtet, und zwei Rap1GAP-Dimere befanden sich in der asymmetrischen 
Einheit des Kristalls. Ein Rap1GAP-Molekül ist aus zwei Domänen aufgebaut, die 
Dimerisierungs- und katalytische Domäne genannt wurden. Sie bestehen jeweils aus 
einem zentralen β-Faltblatt mit umgebenden α-Helices. Die katalytische Domäne 
zeigt überraschend strukturelle Ähnlichkeit zur G-Domäne der kleinen GNBPs. Dies 
deutet auf einen gemeinsamen evolutionären Ursprung von Rap1GAP und den 
GNBPs hin. Zu GAPs anderer Familien konnte keine strukturelle Ähnlichkeit entdeckt 
werden. 
Durch Mutationsanalysen wurde gezeigt, dass die Dimerisierung von Rap1GAP für 
die Katalyse nicht erforderlich ist, aber beide Domänen benötigt werden. Eine Helix in 
der katalytischen Domäne, deren Sequenz in der Rap1GAP-Familie hochkonserviert 
ist, wurde als Interaktionshelix für Rap1 identifiziert. Mutationen in dieser Helix und in 
ihrer unmittelbaren Nähe führen zu starkem GAP-Aktivitätsverlust.  
Mit Hilfe einer fluoreszenzbasierten Nachweisreaktion konnte eindeutig gezeigt 
werden, dass Rap1GAP ein katalytisches Asparagin aus der Interaktionshelix für die 
Katalyse bereitstellt. Eine Mutation dieses Restes zu Alanin inaktiviert Rap1GAP, 
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ohne die Bindung von Rap1•GTP zu beeinflussen. Im Gegensatz zum Wildtyp-
Protein kann die Asparagin-Mutante nicht mit einem Übergangszustands-Analogon 
der Rap1-GTP-Hydrolyse assoziieren. Dies ist das erste Beispiel eines GAPs, das 
ein katalytisches Asparagin zur Katalyse bereitstellt. Mit Hilfe dieses Befundes und 
weiterer Mutationsanalysen wurde ein Interaktionsmodell für Rap1GAP mit Rap1 
erstellt. 
Diese Ergebnisse dieser Arbeit sind für die Krankheit Tuberöse Sklerose relevant, die 
durch inaktivierende Punkt-Mutationen im Rap1GAP-Homologen Tuberin ausgelöst 
werden kann. Die Ursachen des Funktionsverlusts können durch die strukturellen 
und biochemischen Befunde dieser Arbeit besser verstanden werden.  
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